<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">95481</article-id><article-id pub-id-type="doi">10.7554/eLife.95481</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.95481.2</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Structural Biology and Molecular Biophysics</subject></subj-group></article-categories><title-group><article-title>Allosteric coupling asymmetry mediates paradoxical activation of BRAF by type II inhibitors</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-349317"><name><surname>Rasmussen</surname><given-names>Damien M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6828-8520</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-349318"><name><surname>Semonis</surname><given-names>Manny M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-349319"><name><surname>Greene</surname><given-names>Joseph T</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-87043"><name><surname>Muretta</surname><given-names>Joseph M</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-99658"><name><surname>Thompson</surname><given-names>Andrew R</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-349320"><name><surname>Toledo Ramos</surname><given-names>Silvia</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-145332"><name><surname>Thomas</surname><given-names>David D</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8822-2040</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-198415"><name><surname>Pomerantz</surname><given-names>William CK</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-35371"><name><surname>Freedman</surname><given-names>Tanya S</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5168-5829</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-79863"><name><surname>Levinson</surname><given-names>Nicholas M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4338-8087</contrib-id><email>nml@umn.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/017zqws13</institution-id><institution>Department of Pharmacology, University of Minnesota</institution></institution-wrap><addr-line><named-content content-type="city">Minneapolis</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/017zqws13</institution-id><institution>Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota</institution></institution-wrap><addr-line><named-content content-type="city">Minneapolis</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/017zqws13</institution-id><institution>Department of Chemistry, University of Minnesota</institution></institution-wrap><addr-line><named-content content-type="city">Minneapolis</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/017zqws13</institution-id><institution>Center for Immunology, University of Minnesota</institution></institution-wrap><addr-line><named-content content-type="city">Minneapolis</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/017zqws13</institution-id><institution>Masonic Cancer Center, University of Minnesota</institution></institution-wrap><addr-line><named-content content-type="city">Minneapolis</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Andreotti</surname><given-names>Amy H</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04rswrd78</institution-id><institution>Iowa State University</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Andreotti</surname><given-names>Amy H</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04rswrd78</institution-id><institution>Iowa State University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>14</day><month>05</month><year>2024</year></pub-date><volume>13</volume><elocation-id>RP95481</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-01-09"><day>09</day><month>01</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2023-11-15"><day>15</day><month>11</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.04.18.536450"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-04-03"><day>03</day><month>04</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.95481.1"/></event></pub-history><permissions><copyright-statement>Â© 2024, Rasmussen et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Rasmussen et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-95481-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-95481-figures-v1.pdf"/><abstract><p>The type II class of RAF inhibitors currently in clinical trials paradoxically activate BRAF at subsaturating concentrations. Activation is mediated by induction of BRAF dimers, but why activation rather than inhibition occurs remains unclear. Using biophysical methods tracking BRAF dimerization and conformation, we built an allosteric model of inhibitor-induced dimerization that resolves the allosteric contributions of inhibitor binding to the two active sites of the dimer, revealing key differences between type I and type II RAF inhibitors. For type II inhibitors the allosteric coupling between inhibitor binding and BRAF dimerization is distributed asymmetrically across the two dimer binding sites, with binding to the first site dominating the allostery. This asymmetry results in efficient and selective induction of dimers with one inhibited and one catalytically active subunit. Our allosteric models quantitatively account for paradoxical activation data measured for 11 RAF inhibitors. Unlike type II inhibitors, type I inhibitors lack allosteric asymmetry and do not activate BRAF homodimers. Finally, NMR data reveal that BRAF homodimers are dynamically asymmetric with only one of the subunits locked in the active Î±C-in state. This provides a structural mechanism for how binding of only a single Î±C-in inhibitor molecule can induce potent BRAF dimerization and activation.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>BRAF</kwd><kwd>kinase inhibitor</kwd><kwd>paradoxical activation</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>None</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>F31CA257218</award-id><principal-award-recipient><name><surname>Rasmussen</surname><given-names>Damien M</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>R33CA246363</award-id><principal-award-recipient><name><surname>Levinson</surname><given-names>Nicholas M</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>T32GM132029</award-id><principal-award-recipient><name><surname>Rasmussen</surname><given-names>Damien M</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000048</institution-id><institution>American Cancer Society â Kirby Foundation</institution></institution-wrap></funding-source><award-id>PF-21-068-01-LIB</award-id><principal-award-recipient><name><surname>Greene</surname><given-names>Joseph T</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000069</institution-id><institution>National Institute of Arthritis and Musculoskeletal and Skin Diseases</institution></institution-wrap></funding-source><award-id>R01AR073966</award-id><principal-award-recipient><name><surname>Freedman</surname><given-names>Tanya S</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>5R35GM140837</award-id><principal-award-recipient><name><surname>Pomerantz</surname><given-names>William CK</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A comprehensive allosteric model describes how inhibitors can activate rather than inhibit a target kinase by selectively driving formation of kinase dimers with one inhibited and one activated subunit.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The protein kinase BRAF is a central component of the MAPK (RAF-MEK-ERK) signaling pathway and plays a critical role in the regulation of eukaryotic cell growth, proliferation, and survival (<xref ref-type="bibr" rid="bib27">Lavoie and Therrien, 2015</xref>; <xref ref-type="bibr" rid="bib54">Wellbrock et al., 2004</xref>). In quiescent cells, BRAF exists in the cytosol as an autoinhibited monomer (<xref ref-type="bibr" rid="bib36">Park et al., 2019</xref>; <xref ref-type="bibr" rid="bib31">Martinez Fiesco et al., 2022</xref>; <xref ref-type="bibr" rid="bib47">Thevakumaran et al., 2015</xref>). Upon initiation of growth factor signaling, BRAF monomers are recruited to the plasma membrane by RAS-GTP and activated by homodimerization or by heterodimerization with the additional isoforms ARAF and CRAF (<xref ref-type="bibr" rid="bib43">Rushworth et al., 2006</xref>; <xref ref-type="bibr" rid="bib53">Weber et al., 2001</xref>). Dimerization allosterically activates BRAF by triggering a conformational change of the regulatory Î±C-helix from an inactive Î±C-out state to an active Î±C-in state (<xref ref-type="bibr" rid="bib41">Rajakulendran et al., 2009</xref>). Activated BRAF dimers initiate a phosphorylation cascade in which MEK and ERK are sequentially activated by successive phosphorylation events (<xref ref-type="bibr" rid="bib27">Lavoie and Therrien, 2015</xref>).</p><p>Mutations in BRAF play a major role in driving human cancers, most notably in approximately half of melanoma cases (<xref ref-type="bibr" rid="bib8">Davies et al., 2002</xref>). The most prevalent BRAF mutation is V600E (<xref ref-type="bibr" rid="bib35">Owsley et al., 2021</xref>), which confers constitutive kinase activity on BRAF by disrupting critical autoinhibitory interactions, allowing monomeric V600E BRAF to phosphorylate its substrate MEK independently of upstream signaling and dimerization (<xref ref-type="bibr" rid="bib55">Yao et al., 2015</xref>; <xref ref-type="bibr" rid="bib52">Wan et al., 2004</xref>). The FDA-approved inhibitors vemurafenib, dabrafenib, and encorafenib show remarkable initial responses in V600E-driven metastatic melanoma patients due to their effective inhibition of V600E BRAF monomers. However, clinical resistance emerges rapidly and is driven by the formation of mutant BRAF dimers, which these drugs fail to inhibit (<xref ref-type="bibr" rid="bib4">Chapman et al., 2011</xref>; <xref ref-type="bibr" rid="bib16">Hauschild et al., 2012</xref>; <xref ref-type="bibr" rid="bib9">Dummer et al., 2018</xref>). Consequently, mechanisms that promote BRAF dimerization, including receptor tyrosine kinase upregulation, activating RAS mutations, and BRAF splice variants, confer resistance to these inhibitors (<xref ref-type="bibr" rid="bib33">Nazarian et al., 2010</xref>; <xref ref-type="bibr" rid="bib39">Poulikakos et al., 2011</xref>; <xref ref-type="bibr" rid="bib51">Wagle et al., 2011</xref>; <xref ref-type="bibr" rid="bib6">Cook and Cook, 2021</xref>; <xref ref-type="bibr" rid="bib40">Proietti et al., 2020</xref>; <xref ref-type="bibr" rid="bib3">Brummer and McInnes, 2020</xref>). In fact, these inhibitors can paradoxically activate BRAF dimers, leading to elevated MAPK signaling in cells containing dimeric BRAF (<xref ref-type="bibr" rid="bib38">Poulikakos et al., 2010</xref>; <xref ref-type="bibr" rid="bib15">Hatzivassiliou et al., 2010</xref>; <xref ref-type="bibr" rid="bib21">Joseph et al., 2010</xref>). This paradoxical activation triggers the emergence of secondary cutaneous carcinomas in many patients treated with these inhibitors (<xref ref-type="bibr" rid="bib45">Su et al., 2012</xref>).</p><p>The failure of the FDA-approved BRAF inhibitors to block BRAF dimers is attributed to negative allostery, in which inhibitors preferentially bind the inactive Î±C-out state of BRAF and are unable to bind to the active Î±C-in state adopted by BRAF dimers (<xref ref-type="bibr" rid="bib22">Karoulia et al., 2016</xref>). This discovery prompted the development of a new class of inhibitors that recognize the Î±C-in state and bypass this negative allostery (<xref ref-type="bibr" rid="bib37">Peng et al., 2015</xref>; <xref ref-type="bibr" rid="bib34">Okaniwa et al., 2013</xref>). Remarkably, despite binding to both subunits of the BRAF dimer in X-ray structures (<xref ref-type="bibr" rid="bib37">Peng et al., 2015</xref>; <xref ref-type="bibr" rid="bib57">Yen et al., 2021</xref>; <xref ref-type="bibr" rid="bib49">Tkacik et al., 2023</xref>) and being reportedly equipotent for both subunits (<xref ref-type="bibr" rid="bib7">Cotto-Rios et al., 2020</xref>), these Î±C-in inhibitors still induce paradoxical activation of MAPK/ERK signaling in cells (<xref ref-type="bibr" rid="bib38">Poulikakos et al., 2010</xref>; <xref ref-type="bibr" rid="bib57">Yen et al., 2021</xref>; <xref ref-type="bibr" rid="bib7">Cotto-Rios et al., 2020</xref>; <xref ref-type="bibr" rid="bib14">Hall-Jackson et al., 1999</xref>; <xref ref-type="bibr" rid="bib32">Nakamura et al., 2013</xref>; <xref ref-type="bibr" rid="bib25">Lai et al., 2022</xref>). Paradoxical activation by Î±C-in inhibitors is linked to their ability to induce BRAF dimers (<xref ref-type="bibr" rid="bib26">Lavoie et al., 2013</xref>), but the molecular mechanisms triggering this activation remain elusive. Addressing this question could shed light on the shortcomings of numerous drugs currently undergoing clinical trials (<xref ref-type="bibr" rid="bib11">Eisen et al., 2006</xref>; <xref ref-type="bibr" rid="bib46">Sullivan et al., 2020</xref>) and inspire the development of new RAF inhibitors that do not induce paradoxical activation of the MAPK pathway.</p><p>Here, we use biophysical techniques tracking BRAF dimerization, activation, and structural changes in solution, to develop a comprehensive model highlighting the allosteric and thermodynamic mechanisms that underpin paradoxical activation by Î±C-in RAF inhibitors. We demonstrate that all Î±C-in inhibitors are allosterically coupled to BRAF dimerization to a remarkable degree, and further highlight fundamental distinctions in the coupling mechanisms between type I and type II Î±C-in inhibitors that explain key differences in how they induce paradoxical activation.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Type II inhibitors drive BRAF dimerization through asymmetric allosteric coupling</title><p>We used intermolecular FRET to quantify inhibitor-induced BRAF dimerization in vitro. A previously validated construct of the BRAF kinase domain containing 16 solubilizing mutations (<xref ref-type="bibr" rid="bib47">Thevakumaran et al., 2015</xref>; <xref ref-type="bibr" rid="bib50">Tsai et al., 2008</xref>) (hereafter referred to as âBRAFâ) was covalently labeled on K547C with donor (Alexa Fluor 488) or acceptor (Alexa Fluor 568) fluorophores, mixed at equal molar ratios and dispensed into multiwell plates (<xref ref-type="fig" rid="fig1">Figure 1a</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1</xref>). We recorded donor and acceptor emission spectra on a fluorescence plate reader (<xref ref-type="bibr" rid="bib44">Schaaf et al., 2017</xref>) and utilized spectral deconvolution to obtain accurate values for the acceptor/donor (A/D) ratio, from which dimerization was inferred (<xref ref-type="fig" rid="fig1">Figure 1b</xref>). In control experiments without drug, the baseline dimerization affinity of apo BRAF (K<sub>D</sub><sup>dimer</sup>) was found to be 62.4Â±2.9 Î¼M, in agreement with previously reported values (<xref ref-type="bibr" rid="bib26">Lavoie et al., 2013</xref>; <xref ref-type="fig" rid="fig1s2">Figure 1âfigure supplement 2a and b</xref>). We then examined BRAF dimerization in the presence of a diverse set of 11 Î±C-in (3 type I, 8 type II) and 3 Î±C-out RAF inhibitors (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). All Î±C-in inhibitors induced large increases in the A/D ratio, consistent with inhibitor-induced BRAF dimerization (<xref ref-type="fig" rid="fig1">Figure 1b</xref> and <xref ref-type="fig" rid="fig1s3">Figure 1âfigure supplement 3</xref>). The change in A/D ratio with BRAF concentration observed at saturating inhibitor concentrations indicated that inhibitor-bound BRAF dimerizes with nanomolar affinity, representing several orders of magnitude enhancement over baseline dimerization.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Type II Î±C-in inhibitors drive BRAF dimerization through asymmetric allosteric coupling.</title><p>(<bold>a</bold>) Schematic of the intermolecular FRET sensor used to quantify BRAF dimerization. A detailed structrual model of the FRET sensor is shown in <xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1</xref>. (<bold>b</bold>) Representative intermolecular FRET experiments measuring BRAF dimerization by type I Î±C-in inhibitor GDC0879 as a function of BRAF concentration. Dashed lines represent the global fit of these data to the model shown in panel c. Data for all Î±C-in inhibitors are shown in <xref ref-type="fig" rid="fig1s3">Figure 1âfigure supplement 3</xref>. (<bold>c</bold>) Model of inhibitor-induced BRAF dimerization used for the global fitting of FRET data in panel b. B represents apo/unbound BRAF monomer, BD drug/inhibitor-bound monomer, BB apo/unbound dimer, BBD dimeric BRAF with one bound inhibitor molecule, and BBDD dimeric BRAF with two inhibitor molecules bound. These biochemical species are linked by the equilibrium dissociation constants described in the main text and methods. (<bold>d, e</bold>) Equilibrium dissociation constants for dimerization (panel d) and inhibitor binding (panel e) determined from global fitting analysis of the GDC0879 experiments shown in panel b. Allosteric coupling factors Î± and Î² describe the coupling of BRAF dimerization to the first and second inhibitor binding events, respectively (see Materials and methods), and are similar in magnitude for this type I inhibitor. Dissociation constants for all inhibitors are shown in <xref ref-type="fig" rid="fig1s5">Figure 1âfigure supplements 5</xref> and <xref ref-type="fig" rid="fig1s6">6</xref> . (<bold>f</bold>) Allosteric coupling factors Î± and Î², as well as their product Î±Î², are shown for all RAF inhibitors examined. Error bars represent the mean Â± s.e.m.; nâ¥3 independent experiments, each performed in duplicate. (<bold>g</bold>) Plots of the allosteric coupling factor ratio Î±/Î² for all Î±C-in inhibitors. (<bold>h</bold>) Representative intermolecular FRET experiments measuring disruption of BRAF<sup>E586K</sup> dimerization by the Î±C-out inhibitor encorafenib at increasing BRAF concentrations. Dashed lines represent the global fit to the thermodynamic model shown in panel c.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1âsource data 1.</label><caption><title>Tabulated source data for <xref ref-type="fig" rid="fig1">Figure 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95481-fig1-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95481-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 1.</label><caption><title>X-ray structures showing the BRAF dimer labeled with fluorophores and structural features of type I and type II inhibitor binding modes.</title><p>(<bold>a</bold>) X-ray structure (PDB: 5C9C) showing the BRAF dimer covalently labeled at K547 with Alexa Fluor 488 C<sub>5</sub> maleimide using mtsslSuite (<ext-link ext-link-type="uri" xlink:href="http://www.mtsslsuite.isb.ukbonn.de/">http://www.mtsslsuite.isb.ukbonn.de/</ext-link>). (<bold>b</bold>) Stopped flow fluorescence anisotropy data showing labeling of BRAF WT and K547C with Alexa 488. (<bold>c</bold>) X-ray structure of the inactive BRAF monomer (PDB ID: 6PP9) highlighting (dark gray) key regulatory features of the kinase domain including the DFG-motif, Î±C-helix, and activation loop. The structural differences that distinguish type I (yellow) and type II (purple) inhibitors are highlighted and overlaid with the structure of the autoinhibited BRAF monomer (light gray) (PDB IDs: 4MNE, 5C9C).</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1âfigure supplement 1âsource data 1.</label><caption><title>Tabulated source data.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95481-fig1-figsupp1-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95481-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 2.</label><caption><title>Quantifying apo BRAF dimerization affinity (K<sub>D</sub><sup>dimer</sup>) and dimer induction by GDC0879.</title><p>(<bold>a</bold>) Intermolecular FRET experiments tracking BRAF dimerization as a function of GDC0879 concentration were carried out at high BRAF concentrations in order to define the relatively weak apo BRAF dimerization affinity. Black dotted lines represent a global fit to the thermodynamic model shown in <xref ref-type="fig" rid="fig1">Figure 1c</xref> (see Materials and methods). The red arrow highlights apo BRAF dimerization (K<sub>D</sub><sup>dimer</sup>) occurring with no inhibitor. (<bold>b, c</bold>) Representative one-dimensional error surface analysis of the global fit parameters for the FRET data shown in panel a, including equilibrium dissociation constants (<bold>b</bold>) and BRAF concentrations and fluorescence coefficients (<bold>c</bold>). The black dotted line represents the chi2 threshold used to establish 95% CIs for each parameter (see Materials and methods). Note that all parameters shown are well constrained within this limit as indicated by their intersection with the chi2 threshold boundary.</p><p><supplementary-material id="fig1s2sdata1"><label>Figure 1âfigure supplement 2âsource data 1.</label><caption><title>Tabulated source data.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95481-fig1-figsupp2-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95481-fig1-figsupp2-v1.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 3.</label><caption><title>Intermolecular FRET experiments measuring inhibitor-induced BRAF dimerization.</title><p>Representative data for all Î±C-in inhibitors showing BRAF dimerization for type I (yellow) and type II (purple) inhibitors. Gradients from light to dark represent experiments done at increasing BRAF concentrations. Lines are fits of individual titrations to a quadratic binding model in GraphPad Prism and are for illustrative purposes only; all data were globally fit to the thermodynamic model shown in <xref ref-type="fig" rid="fig1">Figure 1c</xref>.</p><p><supplementary-material id="fig1s3sdata1"><label>Figure 1âfigure supplement 3âsource data 1.</label><caption><title>Tabulated source data.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95481-fig1-figsupp3-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95481-fig1-figsupp3-v1.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 4.</label><caption><title>One- and two-dimensional error surfaces show that global fitting yields well-constrained parameters for the allosteric model.</title><p>Representative one-dimensional error surface analyses of the global fit parameters from FRET experiments with the Î±C-in type II inhibitor belvarafenib (<bold>a</bold>) and the Î±C-out inhibitor dabrafenib (<bold>b</bold>). The black dotted line represents the chi2 threshold used to establish 95% CIs for each parameter (see Materials and methods). Note that all parameters shown are well constrained within this limit as indicated by their intersection with the chiÂ² threshold boundary. (<bold>c, d</bold>) Representative two-dimensional confidence contour analyses of the GDC0879 experiment shown in <xref ref-type="fig" rid="fig1s2">Figure 1âfigure supplement 2a</xref>, performed either with BRAF concentrations locked to their experimentally determined values (<bold>c</bold>) or allowed to float during fitting (<bold>d</bold>). All pairwise combinations of unconstrained parameters were systematically varied to test for the presence of well-defined chiÂ² minima and examine covariance between parameters. The color bar shows the chiÂ² ratio with red representing the overall best-fit and yellow representing the chiÂ² threshold boundary for 95% CIs. This analysis shows that all equilibrium constants as well as the allosteric coupling factors Î± and Î², defined by the ratios of specific equilibrium dissociation constants (highlighted boxes, see Materials and methods), are well constrained in both fitting procedures.</p><p><supplementary-material id="fig1s4sdata1"><label>Figure 1âfigure supplement 4âsource data 1.</label><caption><title>Tabulated source data.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95481-fig1-figsupp4-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95481-fig1-figsupp4-v1.tif"/></fig><fig id="fig1s5" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 5.</label><caption><title>Equilibrium dissociation constants derived from global fitting of FRET data for all type II inhibitors.</title><p>Dissociation constants for BRAF dimerization (blue) and inhibitor binding affinity (red) derived from the global fitting analysis of the FRET dimerization data. Allosteric coupling factors Î± and Î² describe the coupling of the first and second inhibitor binding events to BRAF dimerization, respectively (see Materials and methods). For these type II inhibitors the greater value of Î± compared to Î² indicates asymmetric allosteric coupling. Data represent best-fit values from global analysis of n=3 independent experiments performed in duplicate.</p><p><supplementary-material id="fig1s5sdata1"><label>Figure 1âfigure supplement 5âsource data 1.</label><caption><title>Tabulated source data.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95481-fig1-figsupp5-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95481-fig1-figsupp5-v1.tif"/></fig><fig id="fig1s6" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 6.</label><caption><title>Equilibrium dissociation constants derived from global fitting of FRET data for type I Î±C-in and Î±C-out inhibitors.</title><p>Dissociation constants for BRAF dimerization (blue) and inhibitor binding affinity (red) derived from the global fitting analysis of the FRET dimerization data. Allosteric coupling factors Î± and Î² describe the coupling of the first and second inhibitor binding events to BRAF dimerization, respectively (see Materials and methods). The similar values of Î± and Î² for the type I inhibitors (top panels) indicate symmetric allosteric coupling, in contrast to the asymmetrically coupled type II inhibitors shown in <xref ref-type="fig" rid="fig1s5">Figure 1âfigure supplement 5</xref>. The Î±C-out inhibitors (bottom panels) show negative allosteric coupling and weaken BRAF<sup>E586K</sup> dimerization. Data represent best-fit values from global analysis of n=3 independent experiments performed in duplicate.</p><p><supplementary-material id="fig1s6sdata1"><label>Figure 1âfigure supplement 6âsource data 1.</label><caption><title>Tabulated source data.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95481-fig1-figsupp6-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95481-fig1-figsupp6-v1.tif"/></fig><fig id="fig1s7" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 7.</label><caption><title>Inhibitor affinities for monomeric BRAF (K<sub>D</sub><sup>drug</sup>) measured by intramolecular FRET.</title><p>(<bold>a</bold>) Schematic highlighting the equilibrium dissociation constant K<sub>D</sub><sup>drug</sup> that is being independently measured in the context of the thermodynamic model used for global fitting. (<bold>b</bold>) Schematic showing the intramolecular FRET biosensor used to quantify inhibitor binding to monomeric BRAF containing dimer disrupting mutations. Inhibitor-induced conformational changes of the Î±C-helix upon binding lead to a change in FRET. (<bold>c</bold>) Inhibitor binding to monomeric BRAF as indicated by changes in FRET (acceptor/donor ratio). Binding curves were fit to a quadratic binding model in GraphPad Prism to extract K<sub>D</sub><sup>drug</sup>. (<bold>d</bold>) Best-fit values for K<sub>D</sub><sup>drug</sup> measured directly by intramolecular FRET (blue) in panel c compared to best-fit values predicted from the global fitting analysis of intermolecular FRET dimerization data (cream). Data represent the mean Â± s.e.m.; n=3 independent experiments.</p><p><supplementary-material id="fig1s7sdata1"><label>Figure 1âfigure supplement 7âsource data 1.</label><caption><title>Tabulated source data.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95481-fig1-figsupp7-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95481-fig1-figsupp7-v1.tif"/></fig><fig id="fig1s8" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 8.</label><caption><title>The A481F active site mutation blocks inhibitor binding and prevents inhibitor-induced dimerization.</title><p>(<bold>a</bold>) A schematic demonstrating how the A481F active site mutation eliminates the effects of Î² on BRAF dimerization by blocking inhibitor binding and preventing the formation of BRAF dimers with both active sites bound to inhibitors. (<bold>b</bold>) Intermolecular FRET dimerization data showing the formation of BRAF<sup>A481F</sup>/BRAF<sup>A481F</sup> homodimers as a function of Î±C-in inhibitor concentration. Î±C-in inhibitors fail to induce A481F homodimers indicating that the mutation effectively blocks inhibitor binding, with the exception of LY3009120 which, although it binds far more weakly to the mutant, does trigger dimerization at high concentrations.</p><p><supplementary-material id="fig1s8sdata1"><label>Figure 1âfigure supplement 8âsource data 1.</label><caption><title>Tabulated source data.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95481-fig1-figsupp8-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95481-fig1-figsupp8-v1.tif"/></fig><fig id="fig1s9" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 9.</label><caption><title>The binding of a single Î±C-in type II molecule to the BRAF dimer is sufficient to dramatically increase dimerization affinity.</title><p>(<bold>a</bold>) Representative intermolecular FRET dimerization data showing the formation of BRAF<sup>A481F</sup>/BRAF heterodimers (orange) and BRAF/BRAF homodimers (blue) as a function of inhibitor concentration. The type II inhibitors strongly induce BRAF<sup>A481F</sup>/BRAF heterodimers, while the type I inhibitor GDC0879 does not. (<bold>b</bold>) The upper baselines observed at saturating inhibitor concentrations in panel a were fit to a monomer-dimer equilibrium model (left) to obtain estimates of the K<sub>D</sub> values for saturated BBD dimers (right), which agree well with <inline-formula><mml:math id="inf1"><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>Î±</mml:mi></mml:mrow></mml:mfrac></mml:math></inline-formula> K<sub>D</sub><sup>dimer</sup> values calculated from the global fitting analysis of independent FRET experiments.</p><p><supplementary-material id="fig1s9sdata1"><label>Figure 1âfigure supplement 9âsource data 1.</label><caption><title>Tabulated source data.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95481-fig1-figsupp9-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95481-fig1-figsupp9-v1.tif"/></fig><fig id="fig1s10" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 10.</label><caption><title>Intermolecular FRET experiments measuring the disruption of BRAF<sup>E586K</sup> dimerization by Î±C-out inhibitors.</title><p>Representative data showing BRAF<sup>E586K</sup> dimerization as a function of Î±C-out inhibitors (red) and the Î±C-in inhibitor LY3009120 (blue) for comparison. Gradients from light to dark represent experiments done at increasing BRAF concentration. Lines are fits of individual titrations to a quadratic binding model in GraphPad Prism and are for illustrative purposes only; all data were globally fit to the thermodynamic model shown in <xref ref-type="fig" rid="fig1">Figure 1c</xref>.</p><p><supplementary-material id="fig1s10sdata1"><label>Figure 1âfigure supplement 10âsource data 1.</label><caption><title>Tabulated source data.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95481-fig1-figsupp10-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95481-fig1-figsupp10-v1.tif"/></fig><fig id="fig1s11" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 11.</label><caption><title>Only asymmetric allosteric models correspond to realistic levels of catalytic activity of BBD dimers for type II inhibitors.</title><p>(<bold>a</bold>) For some datasets, removing constraints on the BRAF concentrations used in the global fitting analysis resulted in two possible solutions, as shown for a representative case of fitting FRET data obtained with belvarafenib, where a one-dimensional error surface for the [BRAF]<sub>1</sub> concentration parameter reveals two minima. The gray dotted line represents the chi2 threshold used to establish the 95% CI for the [BRAF]<sub>1</sub> parameter. The two minima at different BRAF concentrations with equivalent chiÂ² values correspond to a symmetric and an asymmetric model. (<bold>b</bold>) To independently test each model the induction of partially occupied and presumably active â<italic>BBD</italic>â BRAF dimers was simulated as a function of belvarafenib concentration using either the symmetric (brown) or asymmetric (blue) allosteric models derived from the fitting shown in panel a. Simulations were performed for three independent FRET datasets. Note the asymmetric models yielded much stronger BBD induction than the symmetric models. (<bold>c</bold>) The kinase activity of BRAF was measured in vitro at different belvarafenib concentrations and fit to a bell-shaped dose-response curve to determine peak BRAF activity. (<bold>d</bold>) Peak kinase activity and predicted peak [BBD] were used to calculate the inferred catalytic turnover per BBD dimer from the asymmetric and symmetric models. Values were compared to the previously reported catalytic activity of 14-3-3-bound BRAF dimers (black dotted line) (<xref ref-type="bibr" rid="bib29">Liau et al., 2020</xref>). Note that the inferred activity of BBD dimers predicted by the symmetric model (brown) is far higher than the published value for fully activated and uninhibited BRAF dimers. Conversely, the catalytic activity predicted by the asymmetric model (blue) is in close agreement with the published value and is slightly lower, consistent with one of the two active sites of the dimer being inhibited.</p><p><supplementary-material id="fig1s11sdata1"><label>Figure 1âfigure supplement 11âsource data 1.</label><caption><title>Tabulated source data.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95481-fig1-figsupp11-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95481-fig1-figsupp11-v1.tif"/></fig></fig-group><p>We globally fit the FRET data to an allosteric model describing inhibitor-induced BRAF dimerization previously developed <xref ref-type="bibr" rid="bib23">Kholodenko, 2015</xref>; <xref ref-type="fig" rid="fig1">Figure 1c</xref> and Materials and methods. In this model, dimerization is described by three equilibrium dissociation constants quantifying apo BRAF (B) dimerization (K<sub>D</sub><sup>dimer</sup>: B+BâBB), dimerization with one drug/inhibitor (D) bound (<inline-formula><mml:math id="inf2"><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>Î±</mml:mi></mml:mrow></mml:mfrac></mml:math></inline-formula>K<sub>D</sub><sup>dimer</sup>: B+BDâBBD), and dimerization with two inhibitors bound (<inline-formula><mml:math id="inf3"><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>Î±</mml:mi><mml:mi>Î²</mml:mi></mml:mrow></mml:mfrac></mml:math></inline-formula>K<sub>D</sub><sup>dimer</sup>: BD+BDâBBDD). In turn, inhibitor binding is described by three dissociation constants quantifying binding to monomeric BRAF (K<sub>D</sub><sup>drug</sup>: B+DâBD), binding to apo dimeric BRAF (<inline-formula><mml:math id="inf4"><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>Î±</mml:mi></mml:mrow></mml:mfrac></mml:math></inline-formula>K<sub>D</sub><sup>drug</sup>: BB+DâBBD), and binding to the second subunit of dimeric BRAF already harboring one inhibitor molecule (<inline-formula><mml:math id="inf5"><mml:mfrac><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>Î²</mml:mi></mml:mrow></mml:mfrac></mml:math></inline-formula>K<sub>D</sub><sup>drug</sup>: BBD+DâBBDD). To parameterize this model with experimental data, the FRET experiments were mapped onto the model using one fluorescence coefficient to describe the low-FRET monomeric forms of BRAF (B, BD) and a second coefficient to describe the high-FRET dimeric forms of BRAF (BB, BBD, BBDD) (see Materials and methods). Note that the factors of Â½ and 2 in the above definitions arise from the stoichiometry of the reactions and the existence of two drug binding sites per dimer.</p><p>With the dimerization affinity of apo BRAF (K<sub>D</sub><sup>dimer</sup>) constrained to a value of 62.4 Î¼M (see above), global fitting produced well-constrained values for all other dissociation constants in the model (<xref ref-type="fig" rid="fig1">Figure 1d and e</xref> and <xref ref-type="fig" rid="fig1s2">Figure 1âfigure supplements 2b, c</xref> and <xref ref-type="fig" rid="fig1s4">4</xref>). Importantly, because of the explicit separation of inhibitor-driven dimerization into two steps, the energetic contributions of the first and second inhibitor molecules to dimerization can be resolved and are represented by the allosteric coupling parameters Î± and Î², respectively. The parameter Î± can be interpreted as the degree to which baseline dimerization (K<sub>D</sub><sup>dimer</sup>) is enhanced by a single bound inhibitor molecule (<inline-formula><mml:math id="inf6"><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>Î±</mml:mi></mml:mrow></mml:mfrac></mml:math></inline-formula>K<sub>D</sub><sup>dimer</sup>), while the parameter Î² quantifies any additional stabilization from a second inhibitor molecule (<inline-formula><mml:math id="inf7"><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>Î±</mml:mi><mml:mi>Î²</mml:mi></mml:mrow></mml:mfrac></mml:math></inline-formula>K<sub>D</sub><sup>dimer</sup>) (<xref ref-type="fig" rid="fig1">Figure 1d</xref>).</p><p>The Î±C-in RAF inhibitors can be divided into two classes based on binding mode. While both promote the Î±C-in state, type II inhibitors reach further into the active site than type I inhibitors and trigger an additional conformational change of the catalytic DFG-motif, in which the aspartate and phenylalanine DFG residues swap positions (<xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1c</xref>; <xref ref-type="bibr" rid="bib37">Peng et al., 2015</xref>; <xref ref-type="bibr" rid="bib13">Haling et al., 2014</xref>). For both type I and type II inhibitors, our results showed that the total enhancement in BRAF dimerization from inhibitor binding, represented by the product Î±Î², is remarkably strong, ranging from 3 to 5 orders of magnitude (<xref ref-type="fig" rid="fig1">Figure 1f</xref>). Surprisingly, for the type II inhibitors, including the clinical drugs ponatinib, belvarafenib, and tovorafenib, our global fitting analysis revealed that this allosteric coupling is not evenly distributed across the two drug binding sites of the dimer. Rather, these drugs are coupled to BRAF dimerization in a highly asymmetric manner, with the large majority of dimer promotion provided by the binding of the first inhibitor molecule (Î± values as large as 10<sup>4</sup>), and the contributions from the second inhibitor molecule being orders of magnitude smaller (Î² values no larger than 10<sup>2</sup>) (<xref ref-type="fig" rid="fig1">Figure 1f and g</xref> and <xref ref-type="fig" rid="fig1s5">Figure 1âfigure supplement 5</xref>). In contrast, the allosteric coupling for the type I inhibitors is symmetrical (<xref ref-type="fig" rid="fig1">Figure 1g</xref>), with the Î± and Î² values being approximately equal (<xref ref-type="fig" rid="fig1">Figure 1f</xref> and <xref ref-type="fig" rid="fig1s6">Figure 1âfigure supplement 6</xref>).</p><p>Because of the cyclic paths in the model, the pattern of allosteric coupling described above for dimerization affinities also applies to inhibitor affinities. Due to type II inhibitors having large Î± values and small Î² values, their binding affinity for apo BRAF dimers (<inline-formula><mml:math id="inf8"><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>Î±</mml:mi></mml:mrow></mml:mfrac></mml:math></inline-formula>K<sub>D</sub><sup>drug</sup>) is greatly enhanced compared to their binding affinity to BRAF monomers (K<sub>D</sub><sup>drug</sup>), whereas binding to the second subunit of a partially occupied dimer (<inline-formula><mml:math id="inf9"><mml:mfrac><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>Î²</mml:mi></mml:mrow></mml:mfrac></mml:math></inline-formula>K<sub>D</sub><sup>drug</sup>) is only modestly enhanced (<xref ref-type="fig" rid="fig1s5">Figure 1âfigure supplement 5</xref>). For many of the type II inhibitors the large Î± values boost affinities for the first dimer subunit into the picomolar range while the affinities for the second subunit are substantially weaker. In contrast, type I inhibitors, which have similar Î± and Î² values, bind the first and second subunits of the dimer with comparable affinity (<xref ref-type="fig" rid="fig1">Figure 1e</xref> and <xref ref-type="fig" rid="fig1s6">Figure 1âfigure supplement 6</xref>).</p><p>In our FRET experiments inhibitor binding to BRAF monomers is not observed directly, and its weak affinity (K<sub>D</sub><sup>drug</sup>) emerges as a prediction from the global fit analysis due to cyclic path constraints within the model. To support this prediction and confirm that our model is correctly parameterized, we performed control experiments with an intramolecular FRET sensor that directly detects inhibitor binding by measuring inhibitor-induced movements of the Î±C-helix (<xref ref-type="fig" rid="fig1s7">Figure 1âfigure supplement 7a and b</xref>). Using a mutant construct (BRAF<sup>DB</sup>) that cannot dimerize, we were able to uncouple inhibitor binding from BRAF dimerization and independently confirm the weak inhibitor affinity for BRAF monomers predicted by the allosteric model (see Materials and methods, <xref ref-type="fig" rid="fig1s7">Figure 1âfigure supplement 7c and d</xref> ).</p><p>To independently verify that dimerization by type II inhibitors is driven predominately by Î±, we performed additional FRET experiments where the effects of Î² were eliminated by exploiting the inhibitor-blocking A481F mutation (<xref ref-type="bibr" rid="bib18">Hu et al., 2013</xref>; <xref ref-type="fig" rid="fig1s8">Figure 1âfigure supplement 8a</xref>). In control experiments with BRAF<sup>A481F</sup> labeled with both donor and acceptor, inhibitor-induced dimerization was either not observed or was greatly weakened, confirming that the mutation effectively blocks inhibitor binding (<xref ref-type="fig" rid="fig1s8">Figure 1âfigure supplement 8b</xref>). Acceptor-labeled BRAF<sup>A481F</sup> and donor-labeled wild-type BRAF were mixed at equal molar ratios. Under these conditions, fully occupied wild-type BRAF dimers (BBDD) do not contribute to the FRET signal, and only the BRAF<sup>A481F</sup>:BRAF heterodimers, which can bind only one inhibitor molecule (BBD) and are thus driven only by Î±, lead to observable FRET changes (<xref ref-type="fig" rid="fig1s8">Figure 1âfigure supplement 8a</xref>). In these experiments, type II inhibitors triggered increases in the A/D ratios similar in magnitude to those observed in a donor-matched BRAF:BRAF experiment, indicating a similar extent of dimer induction (<xref ref-type="fig" rid="fig1s9">Figure 1âfigure supplement 9a</xref>). Furthermore, dimerization affinities at saturating inhibitor concentrations were in the low nanomolar range, corresponding to a fold-increase over baseline dimerization of between 10<sup>3</sup> and 10<sup>4</sup>, in good agreement with our measured Î± values for the type II inhibitors (<xref ref-type="fig" rid="fig1s9">Figure 1âfigure supplement 9b</xref>). The type I inhibitor GDC0879, which possesses a far more modest Î± value (<xref ref-type="fig" rid="fig1">Figure 1f</xref>), failed to induce BRAF<sup>A481F</sup>:BRAF heterodimers in this experiment. These results are consistent with the coupling between inhibitor binding and dimerization being highly asymmetric for type II inhibitors, where Î± is the dominant value, and more symmetric for type I inhibitors where Î± is smaller and similar in magnitude to Î².</p><p>We also tested the effects of the Î±C-out inhibitors vemurafenib, dabrafenib, and encorafenib on BRAF dimerization. All three disrupted dimerization to such an extent that no dimerization signal was observed at saturating inhibitor concentrations, preventing the global fit analysis from converging to a constrained solution. To circumvent this, we used the oncogenic mutation E586K (BRAF<sup>E586K</sup>) in the dimer interface to enhance dimerization (<xref ref-type="bibr" rid="bib52">Wan et al., 2004</xref>), allowing us to obtain constrained Î± and Î² values for each Î±C-out inhibitor (<xref ref-type="fig" rid="fig1">Figure 1f and h</xref> and <xref ref-type="fig" rid="fig1s10">Figure 1âfigure supplement 10</xref>). This analysis showed that dimer disruption by Î±C-out inhibitors is weaker than dimer promotion by Î±C-in inhibitors, with total decreases in dimerization affinity of 1â2 orders of magnitude (<xref ref-type="fig" rid="fig1">Figure 1f</xref> and <xref ref-type="fig" rid="fig1s6">Figure 1âfigure supplement 6</xref>). Additionally, dimer disruption is not distributed equally between Î± and Î², with the former dominating for vemurafenib and the latter for dabrafenib and encorafenib (<xref ref-type="fig" rid="fig1">Figure 1f</xref>). These results demonstrate that our approach can quantify a wide range of inhibitor-induced dimerization effects including dimer promotion and disruption. Despite opposite effects on dimerization, both Î±C-in and Î±C-out RAF inhibitors can exhibit asymmetric allosteric coupling, suggesting that they are influenced by an asymmetry that is intrinsic to the BRAF kinase domain.</p></sec><sec id="s2-2"><title>Allosteric asymmetry drives accumulation of partially occupied BRAF dimers</title><p>To understand the functional consequences of asymmetric inhibitor-induced dimerization, we used our parameterized allosteric models to simulate the abundance of each BRAF biochemical species in solution (B, BD, BB, BBD, BBDD) as a function of inhibitor concentration (see Materials and methods). For all Î±C-in inhibitors, simulations predict a bell-shaped curve for the induction of partially occupied BBD dimers that increases with inhibitor concentration and peaks at approximately a 1:2 molar ratio of inhibitor to BRAF, before decreasing at higher concentrations due to the formation of dimers saturated with inhibitor (BBDD) (<xref ref-type="fig" rid="fig2">Figure 2a</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 1</xref>). The BBD induction amplitudes varied for type II inhibitors from 11% to 78% of total BRAF protein, but as a group were substantially higher than the amplitudes associated with the type I inhibitors which ranged from 4% to 11% (<xref ref-type="fig" rid="fig2s2">Figure 2âfigure supplement 2a</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Allosteric asymmetry is the driving force for paradoxical activation by type ll Î±C-in inhibitors.</title><p>(<bold>a</bold>) Representative BRAF kinase activity data (circles, left y-axis) and induction of partially occupied BBD dimers (dashed line, right y-axis), for type II inhibitors LY3009120 and tovorafenib (purple) and the type I inhibitor GDC0879 (yellow). Activity data represent mean values Â± s.e.m.; n=3 independent experiments each performed in duplicate. Activity data for other inhibitors are shown in <xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 1</xref>. BBD induction curves were simulated from the allosteric models parameterized with FRET data. The thickness of the band represents the 95%CI of the best-fit model from n=3 independently parameterized models. Simulations for other inhibitors are shown in <xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 1</xref>. (<bold>b</bold>) Induction landscape where the predicted amplitude of BBD induction is plotted over a wide range of Î± and Î² values. Simulations were performed using an allosteric model where K<sub>D</sub><sup>dimer</sup> and K<sub>D</sub><sup>drug</sup> were kept constant and Î± and Î² were systematically varied. Inhibitors are shown mapped onto the landscape (black symbols) based on their experimentally determined Î± and Î² factors. az, AZ628, bel, belvarafenib, dab, dabrafenib, enc, encorafenib, gdc, GDC0879, ly, LY30019120, L7, L779450, pon, ponatinib, sor, sorafenib, sb, SB590885, tov, tovorafenib, tak, TAK632, vem, vemurafenib, zm, ZM33637. (<bold>c</bold>) The simulated peak BBD induction is shown as a function of coupling asymmetry Î±/Î² at two fixed values of the total coupling strength Î±Î². (<bold>d</bold>) Simulated BBD induction magnitudes versus allosteric coupling ratios (Î±/Î²) for Î±C-in type I (yellow) and Î±C-in type II (purple) inhibitors. Data represent the mean Â± s.e.m.; nâ¥3 independent experiments each performed in duplicate. The dashed line represents a hyperbolic fit to the data and confirms the relationship predicted in panel c. (<bold>e</bold>) Amplitude of BRAF kinase activation measured in vitro as a function of the simulated peak BBD induction for each inhibitor. Kinase activity data represent the mean Â± s.e.m.; n=3 independent experiments each performed in duplicate. The slope of the linear fit, corresponding to the catalytic activity of BBD dimers, is indicated.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2âsource data 1.</label><caption><title>Tabulated source data for <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95481-fig2-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95481-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2âfigure supplement 1.</label><caption><title>Simulations of partially occupied BRAF dimer formation and in vitro kinase activity.</title><p>The formation of partially occupied âBBDâ BRAF dimers was simulated as a function of inhibitor concentration using the allosteric model (<xref ref-type="fig" rid="fig1">Figure 1c</xref>) parameterized for each inhibitor via the global analysis of intermolecular FRET data (see Materials and methods). Multiple independent simulations were performed for each inhibitor based on models parameterized with separate FRET datasets and reported as BBD induction amplitude percent. The mean of these simulations from n=3 independent experiments is shown as a black dotted line with the 95%CI of the best-fit model shown as a light gray band. In vitro phosphorylation of MEK by BRAF was measured as a function of Î±C-in type I (yellow), Î±C-in type II (purple), and Î±C-out (red) inhibitors and overlayed onto the BBD induction amplitude simulations. The inhibitor-induced BRAF activation by the asymmetrically coupled type II inhibitors is far greater than the symmetrically coupled type I inhibitors, in excellent agreement with the allosteric model predictions. Data represent the mean Â± s.e.m.; n=3 independent experiments performed in duplicate.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2âfigure supplement 1âsource data 1.</label><caption><title>Tabulated source data.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95481-fig2-figsupp1-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95481-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2âfigure supplement 2.</label><caption><title>BBD induction amplitude and peak catalytic turnover.</title><p>(<bold>a</bold>) Peak BBD induction amplitudes from individual simulations shown in <xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 1</xref> are shown for type I (yellow) and type II (purple) Î±C-in inhibitors. Data represent the mean Â± s.e.m.; n=3 independent experiments performed in duplicate. (<bold>b</bold>) Peak inhibitor-induced BRAF kinase activity for Î±C-in inhibitors determined by in vitro kinase activity assays measuring MEK phosphorylation by BRAF shown in <xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 1</xref>. Data represent the mean and 95% CIs of peak kinase activity determined by fitting n=3 independent kinase activity experiments done in duplicate to a bell-shaped dose-response model in GraphPad Prism.</p><p><supplementary-material id="fig2s2sdata1"><label>Figure 2âfigure supplement 2âsource data 1.</label><caption><title>Tabulated source data.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95481-fig2-figsupp2-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95481-fig2-figsupp2-v1.tif"/></fig></fig-group><p>To determine how induction of BBD dimers is controlled by the Î± and Î² parameters, we used our allosteric model to simulate BBD formation over a wide range of Î± and Î² parameter space, while keeping apo dimerization affinity (K<sub>D</sub><sup>dimer</sup>) and inhibitor affinity (K<sub>D</sub><sup>drug</sup>) constant. The resulting BBD induction landscape is shown in <xref ref-type="fig" rid="fig2">Figure 2b</xref>. This analysis revealed that the amplitude of BBD induction is primarily dictated by the ratio between Î± and Î², or the degree of asymmetry in the allosteric model, following a hyperbolic relationship with respect to Î±/Î² (<xref ref-type="fig" rid="fig2">Figure 2c</xref>), rather than by the total magnitude of dimer enhancement (Î±Î²). This hyperbolic relationship was also observed with the experimentally parameterized models for the type I and type II inhibitors (<xref ref-type="fig" rid="fig2">Figure 2d</xref>). In fact, different Î±/Î² ratios fully account both for the differences between type I and type II inhibitors and for the variability within the type II class. For instance, among the clinically relevant type II drugs in our set, belvarafenib and ponatinib have the largest Î±/Î² ratios (&gt;10<sup>3</sup>) and induce BBD dimers strongly, tovorafenib has a moderate Î±/Î² ratio (10<sup>2</sup>) and induces dimers moderately well, and sorafenib has the lowest Î±/Î² ratio (30) and is only marginally superior to the type I inhibitors at inducing BBD dimers (<xref ref-type="fig" rid="fig2">Figure 2d</xref>). These observations establish that greater allosteric coupling asymmetry translates into greater induction of partially occupied BBD dimers.</p><p>Comparing the inhibitors in our dataset in terms of their respective Î± and Î² values on the simulated BBD induction landscape clarifies that they occupy three distinct regions. Notably, the type I and type II inhibitors are resolved into separate groups (<xref ref-type="fig" rid="fig2">Figure 2b</xref>). The type II inhibitors are distributed in this space along an axis of increasing Î±/Î² ratio and approximately at right angles to an axis of increasing Î±Î², further highlighting the central role of allosteric asymmetry in determining the amplitude of BBD dimer induction. The Î±C-out inhibitors occupy a region of the landscape where both Î± and Î² are unfavorable, corresponding to dimer disruption rather than dimer promotion. This underscores that paradoxical activation by Î±C-out inhibitors is not driven by the dimer-induction mechanism of Î±C-in inhibitors, but by alternative mechanisms including negative allostery, RAS priming, and transactivation (<xref ref-type="bibr" rid="bib19">Jin et al., 2017</xref>).</p></sec><sec id="s2-3"><title>Induction of partially occupied dimers quantitatively accounts for paradoxical activation in vitro</title><p>To test how the induction of BBD dimers translates into BRAF kinase activity, we used a fluorescence-based kinase assay to directly measure the phosphorylation of recombinant MEK by BRAF. In this assay, type II inhibitors induced strong dose-dependent increases in BRAF activity up to 19-fold above the no-inhibitor control that agreed strikingly well with simulated BBD induction curves (<xref ref-type="fig" rid="fig2">Figure 2a</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 1</xref> and <xref ref-type="fig" rid="fig2s2">2b</xref> ). In contrast, the type I inhibitors induced only relatively minor increases in BRAF activity (<xref ref-type="fig" rid="fig2">Figure 2a</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 1</xref> and <xref ref-type="fig" rid="fig2s2">2b</xref> ), consistent with their weak ability to induce BBD dimers, and the Î±C-out inhibitors vemurafenib and dabrafenib failed to trigger any discernable activation (<xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 1</xref>).</p><p>Comparing the measured amplitudes of kinase activation with the BBD induction amplitudes predicted by the parameterized allosteric models for each inhibitor revealed an impressive linear correlation (R<sup>2</sup>=0.93) (<xref ref-type="fig" rid="fig2">Figure 2e</xref>). The slope of the linear fit yielded a value for the catalytic turnover per BBD dimer of (3.2Â±0.3) Ã 10<sup>â3</sup> s<sup>â1</sup>. This value is in excellent agreement with the turnover value of 4.5Ã10<sup>â3</sup> s<sup>â1</sup> for drug-free BRAF dimers bound to 14-3-3 reported by <xref ref-type="bibr" rid="bib29">Liau et al., 2020</xref>. This observation shows that partially occupied BRAF dimers are highly active and minimally impacted by the presence of one Î±C-in inhibitor molecule, and that the amplitude of paradoxical activation is directly determined by the concentration of this dimer species. The close correspondence between these independent experiments highlights the capability of our allosteric models to accurately predict how RAF inhibitors with a wide range of allosteric effects modulate the concentrations of different BRAF biochemical species to drive paradoxical activation. We conclude that paradoxical activation of BRAF homodimers by type II inhibitors occurs due to asymmetric allosteric coupling that selectively induces catalytically active BBD dimers, rather than fully inhibited BBDD dimers. Because the type I inhibitors lack allosteric asymmetry they cannot activate BRAF by this mechanism (<xref ref-type="fig" rid="fig2">Figure 2d and e</xref>).</p><p>We reasoned that the distinct allosteric coupling of type I and type II inhibitors may be due to the induction of different kinase conformations. Although both type I and II inhibitors are thought to promote the canonical Î±C-in state, the type II inhibitor ponatinib has been proposed to stabilize an intermediate âÎ±C-centerâ conformation (<xref ref-type="bibr" rid="bib7">Cotto-Rios et al., 2020</xref>). Analysis of X-ray structures of BRAF in complex with several other type II inhibitors in our dataset, including AZ628 (<xref ref-type="bibr" rid="bib22">Karoulia et al., 2016</xref>), LY3009120 (<xref ref-type="bibr" rid="bib37">Peng et al., 2015</xref>), and TAK632 (<xref ref-type="bibr" rid="bib34">Okaniwa et al., 2013</xref>), also suggested induction of intermediate Î±C-helix conformations, although crystal packing interactions might contribute to the differences (<xref ref-type="fig" rid="fig3">Figure 3a</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3âfigure supplement 1a</xref>). To test whether type I and type II inhibitors induce distinct Î±C-helix conformations in solution, we performed double electron-electron resonance (DEER) spectroscopy on BRAF by incorporating one nitroxide spin label onto the Î±C-helix (Q493C) and one onto the Î±G-helix (Q664C). This labeling arrangement yields shorter spin-spin distances for the Î±C-in state and longer distances for the Î±C-out state (<xref ref-type="fig" rid="fig3">Figure 3b</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3âfigure supplement 1b and c</xref> ). Distance distributions derived from fitting of the DEER data (see Materials and methods) confirmed that all Î±C-in inhibitors tested induced shorter spin-spin distances relative to apo BRAF, consistent with promotion of the Î±C-in state. However, the type I inhibitor GDC0879 induced a shorter average spin-spin distance than the type II inhibitors AZ628, LY3009120, and TAK632, which yielded distance distributions that were intermediate between those observed with GDC0879 and with apo BRAF (<xref ref-type="fig" rid="fig3">Figure 3b</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3âfigure supplement 1d</xref>). These data confirm that the different binding modes of type I and type II inhibitors are associated with distinct Î±C-helix conformations. Since the conformation of the Î±C-helix is coupled to the N-lobe-to-C-lobe orientation of the kinase, which has been shown to modulate BRAF dimerization (<xref ref-type="bibr" rid="bib26">Lavoie et al., 2013</xref>), these differences likely contribute to the distinct allosteric coupling patterns of type I and type II inhibitors.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Type I and type II inhibitors induce distinct Î±C-helix conformations and promote MAPK/ERK pathway activation in SK-MEL-2 cells.</title><p>(<bold>a</bold>) X-ray structures of BRAF in the apo state (<xref ref-type="bibr" rid="bib36">Park et al., 2019</xref>), bound to the type I inhibitor GDC0879 (<xref ref-type="bibr" rid="bib13">Haling et al., 2014</xref>), and bound to the type II inhibitor AZ628 (<xref ref-type="bibr" rid="bib22">Karoulia et al., 2016</xref>) (PDB IDs: 6PP9, 4MNF, 4RZW), highlighting the different Î±C-helix conformations stabilized by each inhibitor. Structures were aligned on the C-terminal lobe. (<bold>b</bold>) (Left) Schematic of the labeling strategy used to track the conformation of the Î±C-helix with double electron-electron resonance (DEER). (Right) DEER waveforms and Gaussian distance distributions for apo BRAF (gray), BRAF bound to type I inhibitor GDC0879 (yellow), and BRAF bound to the type II inhibitors TAK632, AZ628, and LY3009120 (purple). (<bold>c</bold>) Representative flow-cytometry plots showing gating used to define maximally activated (pMEK<sup>hi</sup>/pERK<sup>hi</sup>) SK-MEL-2 cells in the absence (top) and presence (bottom) of AZ628 at an activating concentration of 100 nM. White labels indicate the % of live, single cells within the maximally activated gate. (<bold>d</bold>) Induction and inhibition of RAF-mediated MAPK phosphorylation in SK-MEL-2 cells treated with the type II inhibitor AZ628 (left, purple) and the type I inhibitor GDC0879 (right, yellow). The overlaid dashed lines represent the inhibitor affinities for the first and second binding sites on the dimer, defined by <inline-formula><mml:math id="inf10"><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>Î±</mml:mi></mml:mrow></mml:mfrac></mml:math></inline-formula>K<sub>D</sub><sup>drug</sup> and <inline-formula><mml:math id="inf11"><mml:mfrac><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>Î²</mml:mi></mml:mrow></mml:mfrac></mml:math></inline-formula>K<sub>D</sub><sup>drug</sup>, respectively, determined from our global fitting analysis. The shaded concentration range between them defines the predicted activation window for each inhibitor. Data represent the mean Â± s.e.m.; n=3 independent experiments. Significance was assessed using one-way ANOVA with Geisser-Greenhouse correction and Tukeyâs multiple comparison test. Asterisks reflect significant paradoxical activation of AZ pairs: [0â20 nM**p=0.0036], [0â100*p=0.0256] and GDC pairs: [0â0.1*p=0.0105], [0â20*p=0.0459]. For both inhibitor titrations, all pairwise comparisons [xâ10,000 nM] also rose to significance and comparisons not mentioned did not. Induction and inhibition of RAF-mediated MAPK phosphorylation in SK-MEL-2 cells treated with additional inhibitors is shown in <xref ref-type="fig" rid="fig3s2">Figure 3âfigure supplement 2</xref>.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3âsource data 1.</label><caption><title>Tabulated source data for <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95481-fig3-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95481-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3âfigure supplement 1.</label><caption><title>Measuring the conformation of the Î±C-helix with double electron-electron resonance (DEER).</title><p>(<bold>a</bold>) X-ray structures of BRAF in the apo state (gray) (PDB ID: 6PP9), bound to type I inhibitors (yellow) (PDB IDs: 4MNF, 2FB8) and type II inhibitors (purple) (PDB IDs: 4RZW, 6P3D, 5C9C, 6XFP, 4KSP, 6V34) highlighting the positioning of the Î±C-helix. Structures were aligned on the C-terminal lobe of the kinase. (<bold>b</bold>) Schematic of the labeling strategy used to track the conformation of the Î±C-helix with DEER. (<bold>c</bold>) MtsslWizard was used to generate predicted spin-spin distance distributions using BRAF crystal structures. Rotamers of 4-maleimido-TEMPO were generated from a GDC0879-bound BRAF structure (PDB ID: 4MNE) adopting an Î±C-in state (yellow) and a structure of apo BRAF (PDB ID: 6PP9) adopting an Î±C-out state (gray). Individual spin-spin distances (dashed lines) were calculated and compiled to simulate spin-spin distances (lower panel) used to assign the Gaussian distance distributions from DEER experiments represented in panel d. (<bold>d</bold>) DEER waveforms and Gaussian distance distributions for apo BRAF and BRAF bound to type I inhibitor GDC0879 (yellow) and type II inhibitors TAK632 and LY3009120 (purple).</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3âfigure supplement 1âsource data 1.</label><caption><title>Tabulated source data.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95481-fig3-figsupp1-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95481-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3âfigure supplement 2.</label><caption><title>Inhibitor-induced MAPK/ERK pathway activation in SK-MEL-2 cells.</title><p>Paradoxical activation of MAPK/ERK signaling in SK-MEL-2 cells by type I (yellow) and type II (purple) RAF inhibitors measured by flow cytometry. The dashed lines represent the inhibitor affinities for the first and second subunit of the BRAF dimer (<inline-formula><mml:math id="inf12"><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>Î±</mml:mi></mml:mrow></mml:mfrac></mml:math></inline-formula> K<sup>drug</sup> and <inline-formula><mml:math id="inf13"><mml:mfrac><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>Î²</mml:mi></mml:mrow></mml:mfrac></mml:math></inline-formula> K<sup>drug</sup>, respectively), determined from the global fitting analysis with the shaded gap between the two lines representing the predicted window of activation. Error bars represent the mean Â± s.e.m.; n=3 independent experiments. Significance was determined from a one-way ANOVA/Geisser-Greenhouse/Tukeyâs test. Asterisks reflect significant paradoxical activation between pairs of data points for GDC0879 [0â0.1 nM,*p=0.0105], [0â20*p=0.0459]; SB590885 [0â100**p=0.0085], [0.1â100**p=0.0064]; AZ628 [0â20**p=0.0036], [0â100*p=0.0256]; belvarafenib [0.1â1*p=0.0250], [0.1â100*p=0.0105]; ponatinib [1â20*p=0.0135]; tovorafenib [0.1â1*p=0.0328]; and TAK632 [0â20*p=0.0249], [0.1â20*p=0.0361]. Most pairwise comparisons [xâ10,000 nM] also rose to significance while comparisons not mentioned did not.</p><p><supplementary-material id="fig3s2sdata1"><label>Figure 3âfigure supplement 2âsource data 1.</label><caption><title>Tabulated source data.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95481-fig3-figsupp2-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95481-fig3-figsupp2-v1.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3âfigure supplement 3.</label><caption><title>Western blot confirming the presence of all RAF isoforms in SK-MEL-2 cells.</title><p>SK-MEL-2 cells were treated with the indicated amount of type II inhibitor AZ628 or type I inhibitor GDC0879 for 1 hr. Cell lysates were immunoblotted for all endogenous RAF isoforms. Note that ARAF, BRAF, and CRAF are present at similar levels.</p><p><supplementary-material id="fig3s3sdata1"><label>Figure 3âfigure supplement 3âsource data 1.</label><caption><title>Uneditited western blots.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95481-fig3-figsupp3-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95481-fig3-figsupp3-v1.tif"/></fig></fig-group></sec><sec id="s2-4"><title>Allosteric asymmetry creates a concentration window for paradoxical activation in cells</title><p>A key feature of our allosteric coupling models is that the asymmetry, represented by the Î±/Î² values, generates differences in the affinities for the first (<inline-formula><mml:math id="inf14"><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>Î±</mml:mi></mml:mrow></mml:mfrac></mml:math></inline-formula>K<sub>D</sub><sup>drug</sup>) and second inhibitor (<inline-formula><mml:math id="inf15"><mml:mfrac><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>Î²</mml:mi></mml:mrow></mml:mfrac></mml:math></inline-formula>K<sub>D</sub><sup>drug</sup>) molecules. We hypothesized that these differences would dictate the inhibitor concentration ranges at which paradoxical activation occurs in cells. To test this prediction, we assessed RAF-induced MAPK pathway activation in SK-MEL-2 melanoma cells expressing wild-type BRAF and a gain-of-function variant of N-RAS (Q61R). Inhibitor-induced activation of MAPK signaling by RAF kinases was measured by flow cytometry, using intracellular staining with antibodies specific for phosphorylated (p)MEK1/2 and pERK1/2 (<xref ref-type="fig" rid="fig3">Figure 3c</xref>).</p><p>The type II inhibitors in our dataset all induced dose-dependent increases of pMEK1/2 and pERK1/2 indicating activation of the MAPK signaling pathway (<xref ref-type="fig" rid="fig3">Figure 3d</xref> and <xref ref-type="fig" rid="fig3s2">Figure 3âfigure supplement 2</xref>; <xref ref-type="bibr" rid="bib38">Poulikakos et al., 2010</xref>; <xref ref-type="bibr" rid="bib22">Karoulia et al., 2016</xref>; <xref ref-type="bibr" rid="bib57">Yen et al., 2021</xref>; <xref ref-type="bibr" rid="bib7">Cotto-Rios et al., 2020</xref>; <xref ref-type="bibr" rid="bib26">Lavoie et al., 2013</xref>). Several predictions from our in vitro allosteric model of paradoxical activation by Î±C-in RAF inhibitors are indeed reinforced by these experiments. First, many type II inhibitors activate the MAPK/ERK signaling pathway at inhibitor concentrations below 1 nM, consistent with ultrapotent inhibitor binding to the first site on the dimer that arises from the extreme allosteric coupling between inhibitor and BRAF dimerization (<xref ref-type="fig" rid="fig3">Figure 3d</xref> and <xref ref-type="fig" rid="fig3s2">Figure 3âfigure supplement 2</xref> ). Second, the concentrations at which activation and inhibition occur differ by several orders of magnitude. These broad activation windows are consistent with the allosteric model, which predicts that the most asymmetric type II inhibitors including LY3009120, AZ628, ponatinib, and belvarafenib will have the largest activation windows (<xref ref-type="fig" rid="fig3">Figure 3d</xref> left panel and <xref ref-type="fig" rid="fig3s2">Figure 3âfigure supplement 2</xref>). Indeed, plotting <inline-formula><mml:math id="inf16"><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>Î±</mml:mi></mml:mrow></mml:mfrac></mml:math></inline-formula>K<sub>D</sub><sup>drug</sup> and <inline-formula><mml:math id="inf17"><mml:mfrac><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>Î²</mml:mi></mml:mrow></mml:mfrac></mml:math></inline-formula>K<sub>D</sub><sup>drug</sup> onto the activation curves shows that the allosteric models provide reasonable bounds on the concentration regime in which paradoxical activation is observed in cells (<xref ref-type="fig" rid="fig3">Figure 3d</xref> and <xref ref-type="fig" rid="fig3s2">Figure 3âfigure supplement 2</xref>).</p><p>Because of the symmetric allosteric coupling of the type I inhibitors the predicted affinities for each BRAF dimer subunit are comparable, indicating that there should be almost no activation window for these inhibitors. Nonetheless, we observed MAPK pathway activation by the type I inhibitors GDC0879, SB590885, and L779450 in SK-MEL-2 cells (<xref ref-type="fig" rid="fig3">Figure 3d</xref> right panel and <xref ref-type="fig" rid="fig3s2">Figure 3âfigure supplement 2</xref>) across a wide concentration range, as seen with the type II inhibitors. This discrepancy suggests that MAPK activation by type I inhibitors is not mediated by BRAF homodimers but instead by BRAF:CRAF heterodimers. In support of this, activation by GDC0879 depends on the presence of CRAF (<xref ref-type="bibr" rid="bib15">Hatzivassiliou et al., 2010</xref>), and both GDC0879 and SB590885 promote BRAF:CRAF heterodimers to a greater extent than the type II inhibitors AZ628 and sorafenib (<xref ref-type="bibr" rid="bib15">Hatzivassiliou et al., 2010</xref>; <xref ref-type="bibr" rid="bib19">Jin et al., 2017</xref>). Furthermore, type I inhibitors are less effective at inhibiting CRAF than type II inhibitors, preventing them from fully inhibiting the BRAF:CRAF heterodimers they induce (<xref ref-type="bibr" rid="bib15">Hatzivassiliou et al., 2010</xref>; <xref ref-type="bibr" rid="bib17">Heidorn et al., 2010</xref>). We have confirmed by immunoblot that SK-MEL-2 cells express all RAF isoforms at comparable levels, indicating that activation through BRAF:CRAF heterodimers is a plausible model for these inhibitors (<xref ref-type="fig" rid="fig3s3">Figure 3âfigure supplement 3</xref>). These observations suggest that type I inhibitors activate by a distinct but related dimer-induction mechanism compared to the type II inhibitors, where differential drug binding to the two dimer subunits is achieved not by allosteric asymmetry but by the drugs having inherently different affinities for the BRAF and CRAF subunits.</p></sec><sec id="s2-5"><title>The BRAF dimer is not locked in the Î±C-in state but dynamically samples multiple conformations</title><p>To gain further insight into the mechanism underlying asymmetric allosteric coupling, we used <sup>19</sup>F NMR to study the conformational dynamics of the BRAF Î±C-helix by incorporating a cysteine-reactive trifluoromethyl NMR probe 3-bromo-1,1,1-trifluoroacetone (BTFA) on the Î±C-helix (Q493C). Spectra of labeled apo BRAF showed two well-resolved resonances at â84.29 and â84.42 ppm (<xref ref-type="fig" rid="fig4">Figure 4a</xref>). Resonance assignment was achieved by adding saturating concentrations of ATP, known to induce the Î±C-out state. From this, the upfield resonance was defined as the Î±C-out (monomeric) state and the downfield resonance as the Î±C-in (dimeric) state (<xref ref-type="fig" rid="fig4s1">Figure 4âfigure supplement 1a</xref>). Increasing the concentration of BRAF led to an increase in the Î±C-in peak area and a relative decrease in the Î±C-out peak area that fit to a monomer-dimer equilibrium with a K<sub>D</sub> of 32.2Â±9.4 Î¼M, in reasonable agreement with the FRET experiments (<xref ref-type="fig" rid="fig4s1">Figure 4âfigure supplement 1b</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>The Î±C-helix in the BRAF dimer dynamically samples multiple conformational states.</title><p>(<bold>a</bold>) <sup>19</sup>F NMR spectrum of apo BRAF labeled on the Î±C-helix (Q493C) with 3-bromo-1,1,1-trifluoroacetone (BTFA). The raw spectrum (gray line) was fit to a multi-component Lorentzian model (dotted line). The deconvoluted spectrum consists of three unique resonances that correspond to one Î±C-out state (red) and two Î±C-in states (blue and yellow). Resonance assignments are shown in <xref ref-type="fig" rid="fig4s1">Figure 4âfigure supplement 1a,b and c</xref> (<bold>b</bold>) Representative <sup>19</sup>F NMR T<sub>2</sub> relaxation profiles showing the peak areas of individual deconvoluted peaks shown in panel a as a function of T<sub>2</sub> decay time. T<sub>2</sub> decay parameters for each component were extracted by single-exponential fits. The inset shows a comparison of these T<sub>2</sub> values with T<sub>2</sub>* values calculated from the spectral line widths of each component via the relationship T<sub>2</sub>*=1/(Ï Ã line width). Data represent the mean Â± s.e.m.; n=4 independent experiments. (<bold>c</bold>) Variable-temperature <sup>19</sup>F NMR experiments. Spectra collected at lowest (light blue) to highest (dark blue) temperatures are shown. The deconvoluted dimer peaks are also shown as dotted lines for the lowest temperature. The inset shows the relative peak areas of Î±C-in<sup>narrow</sup> (yellow) and Î±C-in<sup>broad</sup> (blue) peaks as a function of temperature. Data represent the mean Â± s.e.m.; n=3 independent experiments. (<bold>d</bold>) Schematic representation of our model for how dynamic heterogeneity in the BRAF dimer contributes to paradoxical activation. The relatively static Î±C-in<sup>narrow</sup> (yellow) and more dynamic Î±C-in<sup>broad</sup> (blue) states observed by <sup>19</sup>F NMR experiments are highlighted in the context of drug binding to monomers and dimers, with the biochemical species arranged in the same manner as in <xref ref-type="fig" rid="fig1">Figure 1c</xref>. This model can be further visualized with a free-energy diagram showing the Î±C-in<sup>narrow</sup> and Î±C-in<sup>broad</sup> states similarly populated and in slow exchange. The Î±C-in<sup>broad</sup> state consists of multiple conformational states separated by small energy barriers resulting in exchange on the intermediate timescale.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4âsource data 1.</label><caption><title>Tabulated source data for <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95481-fig4-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95481-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4âfigure supplement 1.</label><caption><title><sup>19</sup>F NMR resonance assignments and experiments confirming the presence of dynamic heterogeneity within the BRAF dimer.</title><p>(<bold>a</bold>) <sup>19</sup>F NMR spectra of BRAF labeled on the Î±C-helix with 3-bromo-1,1,1-trifluoroacetone (BTFA) in the presence of ATP. ATP causes an increase in the upfield resonance and decrease in the downfield resonance, allowing the upfield resonance to be assigned to the monomer/Î±C-out state and the downfield resonance to be assigned to the dimer/Î±C-in state. (<bold>b</bold>)<sup>19</sup>F NMR spectra of BRAF at different BRAF concentrations. The relative peak areas of the Î±C-in peak versus the Î±C-out peak were plotted as a function of BRAF concentration (upper right) and fit to a monomer-dimer equilibrium model (blue), to derive a value for the dimerization affinity which was in reasonable agreement with the value determined from the FRET experiments (dotted line) with a K<sub>D</sub><sup>dimer</sup> of 32.2Â±9.4 Î¼M. (<bold>c</bold>) <sup>19</sup>F NMR spectra of BRAF (gray) and BRAF containing dimer disrupting mutations (BRAF<sup>DB+Q493C</sup>, blue). The disappearance of the downfield resonance in the presence of the dimer disrupting mutations is consistent with the resonance assignments discussed in <bold>a,b</bold> and supports the assignment of the exchange broadened peak to the dimeric state. (<bold>d</bold>) Line widths extracted from deconvoluted <sup>19</sup>F NMR spectra corresponding to the individual species represented in <xref ref-type="fig" rid="fig4">Figure 4a</xref>. Data represent the best-fit values from the spectral deconvolution of n=8 independent experiments. (<bold>e</bold>) <sup>19</sup>F NMR T<sub>2</sub> relaxation profiles obtained from BRAF. Intensities at â84.42 ppm (green) and â84.29 ppm (black) corresponding to the Î±C-out and Î±C-in resonances, respectively, were plotted as a function of decay time. Relaxation profiles required a multi-exponential fit (pË0.0001) indicating the presence of overlapping resonances with distinct relaxation times. Data represent the mean Â± s.e.m.; n=15 independent experiments. (<bold>f</bold>) Solvent isotope effect experiments obtained with BRAF in 10% D<sub>2</sub>O (dotted lines) and 90% D<sub>2</sub>O (solid lines). Individual component fits from spectral deconvolution are shown and correspond to the Î±C-out (red), Î±C-in<sup>narrow</sup> (yellow), and Î±C-in<sup>broad</sup> (blue) states. Relative peak shifts indicate that the two Î±C-in states exhibit a similar degree of solvent exposure. (<bold>g</bold>) Vanât Hoff plot showing the temperature dependence of the equilibrium between the Î±C-in<sup>narrow</sup> and Î±C-in<sup>broad</sup> dimer states.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4âfigure supplement 1âsource data 1.</label><caption><title>Tabulated source data.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95481-fig4-figsupp1-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95481-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4âfigure supplement 2.</label><caption><title>Validation of BRAF labeling, stability, and purity.</title><p>(<bold>a</bold>) Mass spectra of BRAF<sup>16mut</sup> (theoretical molecular weight: 32,204 Da), BRAF<sup>DB+Q493C+Q664C</sup> labeled with two 4-maleimido-TEMPO spin probes (theoretical molecular weight: 32,638 Da), BRAF<sup>Q493C</sup> labeled with 3-bromo-1,1,1-trifluoroacetone (BTFA, theoretical molecular weight: 32,205 Da), BRAF<sup>K547C</sup> (32,178 Da) labeled with Alexa Flour 488 (theoretical molecular weight: 32,900 Da), BRAF<sup>K547C</sup> (32,178 Da) labeled with Alexa Fluor 568 (theoretical molecular weight: 33,060 Da). (<bold>b</bold>) Circular dichroism spectra of BRAF<sup>Q493C</sup> (tan) and BRAF<sup>Q493C</sup> labeled with BTFA (orange). Ellipticity at 220 nm was plotted as a function of temperature. Note that the presence of the BTFA probe does not influence the melting temperature (T<sub>m</sub>) which is well above the maximum temperature used in NMR experiments (red dotted line). (<bold>c</bold>) SDS-PAGE gel of BRAF<sup>K547C</sup> at increasing total protein amounts showing the purity of the samples used in intermolecular FRET experiments.</p><p><supplementary-material id="fig4s2sdata1"><label>Figure 4âfigure supplement 2âsource data 1.</label><caption><title>Tabulated source data.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95481-fig4-figsupp2-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s2sdata2"><label>Figure 4âfigure supplement 2âsource data 2.</label><caption><title>Raw gel from panel c.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95481-fig4-figsupp2-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95481-fig4-figsupp2-v1.tif"/></fig></fig-group><p>Spectral deconvolution of the apo BRAF data revealed an additional resonance underneath the Î±C-in peak (<xref ref-type="fig" rid="fig4">Figure 4a</xref>). This second Î±C-in resonance, referred to as âÎ±C-in<sup>broad</sup>â, is substantially exchange-broadened, with a fitted line width approximately five times that of the narrower overlapping Î±C-in resonance, hereafter referred to as âÎ±C-in<sup>narrow</sup>â (<xref ref-type="fig" rid="fig4s1">Figure 4âfigure supplement 1d</xref>). The presence of the Î±C-in<sup>broad</sup> state was independently confirmed in transverse relaxation (T<sub>2</sub>) experiments, where the peak intensity of the Î±C-in resonance was measured as a function of the transverse magnetization evolution time and fit to an exponential decay model (<xref ref-type="fig" rid="fig4s1">Figure 4âfigure supplement 1e</xref>). A double exponential fit was necessary to adequately describe these data (extra sum-of-squares F-test; p&lt;0.0001), demonstrating the presence of two overlapping species with distinct relaxation times. Spectral deconvolution of these relaxation data produced an estimate of the relaxation times (T<sub>2</sub>) for each peak that were in good agreement with calculated relaxation times (T<sub>2</sub>*) derived from the observed line widths (<xref ref-type="fig" rid="fig4">Figure 4b</xref>). The short relaxation time of the Î±C-in<sup>broad</sup> resonance (&lt;5 ms) is consistent with chemical exchange arising from the conformational dynamics of the Î±C-helix.</p><p>Four independent observations indicate that the Î±C-in<sup>broad</sup> resonance arises from a dimeric species: (1) the chemical shift of this species was similar to that of the Î±C-in<sup>narrow</sup> resonance (<xref ref-type="fig" rid="fig4">Figure 4a</xref>), (2) spectral deconvolution revealed a concentration dependence for the area of the Î±C-in<sup>broad</sup> peak that fits to a monomer-dimer equilibrium model closely agreeing with independent measurements (<xref ref-type="fig" rid="fig4s1">Figure 4âfigure supplement 1b</xref>), (3) the Î±C-in<sup>broad</sup> resonance was not observed in BRAF samples with dimer-disrupting interface mutations (<xref ref-type="fig" rid="fig4s1">Figure 4âfigure supplement 1c</xref>), (4) D<sub>2</sub>O exchange experiments revealed large and nearly identical isotope shifts for the Î±C-in<sup>narrow</sup> and Î±C-in<sup>broad</sup> resonances (0.047 vs 0.050 ppm), indicating a similar degree of solvent exposure of the probe, compared to a relatively small shift for the Î±C-out monomer peak (0.019 ppm) (<xref ref-type="fig" rid="fig4s1">Figure 4âfigure supplement 1f</xref>).</p><p>Furthermore, as the experimental temperature was raised from 2Â°C to 34Â°C, the Î±C-in<sup>broad</sup> peak width decreased, consistent with faster exchange kinetics arising from increased conformational dynamics (<xref ref-type="fig" rid="fig4">Figure 4c and d</xref>). At the same time, the Î±C-in<sup>broad</sup> peak area decreased and the Î±C-in<sup>narrow</sup> peak area increased in a reciprocal manner, indicating a shifting equilibrium between the two dimeric states (<xref ref-type="fig" rid="fig4">Figure 4c</xref>). The equilibrium constant for this process, derived from the ratio of the integrated areas of the Î±C-in<sup>broad</sup> and Î±C-in<sup>narrow</sup> resonances, showed a linear dependence on temperature (<xref ref-type="fig" rid="fig4s1">Figure 4âfigure supplement 1g</xref>).</p><p>Based on these results, we propose the following model (<xref ref-type="fig" rid="fig4">Figure 4d</xref>): The individual subunits of the BRAF dimer transition between two states with strikingly different dynamics. In one state, the subunit is locked in the Î±C-in conformation, with the Î±C-helix relatively static (Î±C-in<sup>narrow</sup>). In the other, more dynamic state, the Î±C-helix undergoes transitions between conformational substates (Î±C-in<sup>broad</sup>). Although our results do not define exactly how the two subunits of the dimer sample these different states, the dynamic Î±C-in state is populated under all experimental conditions. This indicates that BRAF dimers are not constrained in a symmetrical Î±C-in/Î±C-in configuration, as structural models suggest (<xref ref-type="bibr" rid="bib36">Park et al., 2019</xref>; <xref ref-type="bibr" rid="bib29">Liau et al., 2020</xref>), but rather that one subunit is free to explore other conformations. This explains how the binding of a single type II inhibitor molecule, which pays the energetic penalty for locking one BRAF subunit in the Î±C-in state, can dramatically increase BRAF dimerization, since the BRAF dimer only requires one and not both subunits to adopt the locked Î±C-in conformation. Equivalently, compared to the affinity for BRAF monomers, the drug affinity for dimers is greatly enhanced for one subunit and not for both because dimer formation only pays the energetic penalty of locking one subunit in the Î±C-in state. Thus, the dynamic heterogeneity of the BRAF dimer revealed by NMR may form the foundation for the asymmetric allosteric coupling that gives rise to paradoxical activation of BRAF by type II inhibitors.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The FDA-approved Î±C-out RAF inhibitors and the newer Î±C-in RAF inhibitors currently under development represent fundamentally different classes of drug that have opposite effects on RAF conformation and dimerization. Nonetheless, both drug classes trigger paradoxical activation of BRAF. Activation by the Î±C-out inhibitors is attributed in part to negative allostery, where dimer-disrupting allosteric effects prevent full occupancy of intact dimers (<xref ref-type="bibr" rid="bib22">Karoulia et al., 2016</xref>). This model of negative allostery does not provide an adequate explanation for paradoxical activation by Î±C-in inhibitors, which are positively coupled to dimerization and have been thought to bind both subunits of the dimer with equal potency (<xref ref-type="bibr" rid="bib7">Cotto-Rios et al., 2020</xref>).</p><p>Here, we use a series of spectroscopic approaches paired with thermodynamic modeling and global fitting to quantify how inhibitor binding to each subunit of the BRAF dimer is coupled to BRAF dimerization. By explicitly separating inhibitor-induced dimerization into two steps, the allosteric effects from the binding of each inhibitor molecule, along with their respective binding affinities for each BRAF dimer subunit, are resolved. This analysis confirms that, unlike the dimer-disrupting Î±C-out inhibitors, the Î±C-in inhibitors dramatically increase BRAF dimerization affinity. Remarkably, for type II inhibitors this favorable allostery is not evenly distributed between both binding sites of the dimer, as previously proposed (<xref ref-type="bibr" rid="bib7">Cotto-Rios et al., 2020</xref>), and instead occurs through an asymmetric coupling mechanism in which the binding of the first inhibitor molecule promotes dimerization much more strongly than binding of the second inhibitor molecule. This allosteric coupling also causes these inhibitors to have higher affinity for the first subunit of the dimer than for the second subunit. We demonstrate that this allosteric asymmetry triggers selective induction of BRAF dimers with only one subunit bound to inhibitor, with larger degrees of asymmetry leading to greater induction of these partially occupied dimers.</p><p>By combining our allosteric models of inhibitor-induced dimer induction with measurements of BRAF catalytic activity, we show that partially occupied BRAF dimers possess activity equivalent to fully activated inhibitor-free BRAF dimers, explaining their potent activating potential. Indeed, the degree of induction of partially occupied dimers fully accounts for both the concentration dependence and amplitude of BRAF activation measured in vitro for 11 different Î±C-in inhibitors. These results form the basis of a quantitative model for paradoxical activation of BRAF homodimers by Î±C-in inhibitors, where the apparent symmetry afforded by a dimer composed of identical subunits can be broken by asymmetric allosteric coupling between inhibitor binding and dimerization. The predictions of this model for the type II inhibitors are borne out in melanoma cells where the difference in affinities of the first and second inhibitor molecules for the dimer, <inline-formula><mml:math id="inf18"><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>Î±</mml:mi></mml:mrow></mml:mfrac></mml:math></inline-formula>K<sub>D</sub><sup>drug</sup> and <inline-formula><mml:math id="inf19"><mml:mfrac><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>Î²</mml:mi></mml:mrow></mml:mfrac></mml:math></inline-formula>K<sub>D</sub><sup>drug</sup>, equivalent to the allosteric asymmetry Î±/Î², is reflected in a wide concentration gap between where MAPK activation and inhibition are observed.</p><p>Comparing our mechanistic biophysical data with activation patterns observed in cells allowed us to uncover a key distinction between type I and type II inhibitors. While type II inhibitors are asymmetrically coupled and strongly activate BRAF homodimers, type I inhibitors lack sufficient allosteric coupling asymmetry to induce paradoxical activation through this mechanism. We demonstrate, however, that type I inhibitors induce MAPK pathway activation in melanoma cells, consistent with previous reports (<xref ref-type="bibr" rid="bib38">Poulikakos et al., 2010</xref>; <xref ref-type="bibr" rid="bib15">Hatzivassiliou et al., 2010</xref>; <xref ref-type="bibr" rid="bib17">Heidorn et al., 2010</xref>). These observations point to type I inhibitors inducing paradoxical activation through BRAF:CRAF heterodimers, rather than BRAF homodimers, a hypothesis that is consistent with a large body of published work (<xref ref-type="bibr" rid="bib15">Hatzivassiliou et al., 2010</xref>; <xref ref-type="bibr" rid="bib22">Karoulia et al., 2016</xref>; <xref ref-type="bibr" rid="bib19">Jin et al., 2017</xref>; <xref ref-type="bibr" rid="bib17">Heidorn et al., 2010</xref>). Because type I inhibitors bind less tightly to CRAF than BRAF, the subunits of a heterodimer will have inherently different drug affinities, providing a window for paradoxical activation in the absence of allosteric asymmetry. Such a mechanism potentially applies to any dimer-promoting inhibitor with differing affinities for ARAF, BRAF, and CRAF, and would be expected to supplement asymmetry arising from the allosteric coupling mechanism we have uncovered. In particular, the emergence of clinical resistance to belvarafenib and another type II inhibitor, naporafenib, can be mediated by induction of ARAF (<xref ref-type="bibr" rid="bib57">Yen et al., 2021</xref>; <xref ref-type="bibr" rid="bib49">Tkacik et al., 2023</xref>). Since both belvarafenib and naporafenib bind ARAF less potently than BRAF, the disparity in drug affinities for the first and second subunits of ARAF/BRAF heterodimers is likely further boosted over that arising from asymmetric allosteric coupling alone, sustaining activation at higher drug concentrations and conferring resistance.</p><p>Exactly why type II inhibitors are more asymmetrically coupled to BRAF dimerization than type I inhibitors is not entirely clear. It is established that the conformational changes of the Î±C-helix induced by Î±C-in inhibitors also alter the relative orientations of the N-lobe and C-lobe of the kinase, improving the surface complementarity at the dimer interface and enhancing dimerization (<xref ref-type="bibr" rid="bib26">Lavoie et al., 2013</xref>). We show that type I and type II inhibitors stabilize distinct Î±C-helix conformations in solution. In addition, type II inhibitors trigger a structural change of the catalytic DFG-motif and activation loop of BRAF that is not accomplished by type I inhibitors. It is likely that these collective differences unlock the allosteric coupling asymmetry that defines the activating potential of type II inhibitors, but additional biophysical characterization is needed to confirm this.</p><p>Our data reveal that the subunits of the BRAF dimer are not symmetrically locked in the Î±C-in state, as suggested by static structural models, but rather exist in an equilibrium between a rigid Î±C-in state and a dynamic state in which the Î±C-helix conformation fluctuates on the Î¼s-ms timescale. We interpret this as an indication that the BRAF dimer requires only one subunit to adopt the Î±C-in state, providing a straightforward explanation for why the binding of only one Î±C-in inhibitor molecule can dramatically increase dimerization affinity. The recent cryo-EM structure of dimeric BRAF in complex with the scaffolding protein 14-3-3, determined in the absence of inhibitors, shows an asymmetric arrangement of the BRAF dimer with respect to 14-3-3 (<xref ref-type="bibr" rid="bib24">Kondo et al., 2019</xref>). This arrangement permits the C-terminal tail of one subunit to bind to and block the active site of the opposite subunit, while the reciprocal interaction is prevented. This further underscores the nonequivalence of the two subunits of the BRAF dimer and suggests that the dynamic asymmetry we observed in our NMR experiments may be an indication of broader functional asymmetry in BRAF signaling (<xref ref-type="bibr" rid="bib18">Hu et al., 2013</xref>; <xref ref-type="bibr" rid="bib28">Lavoie et al., 2018</xref>).</p><p>It is interesting to consider the preclinical and clinical experience with type II RAF inhibitors in light of our results. Several type II inhibitors studied here including belvarafenib (NCT04835805) and LY3009120 (NCT02014116) have entered clinical trials or could be repurposed like the FDA-approved chronic myeloid leukemia drug ponatinib. It is claimed that these molecules show minimal paradoxical activation compared to vemurafenib (<xref ref-type="bibr" rid="bib57">Yen et al., 2021</xref>; <xref ref-type="bibr" rid="bib7">Cotto-Rios et al., 2020</xref>). However, paradoxical activation by these type II inhibitors has been observed in cell lines both with and without elevated RAS activity (<xref ref-type="bibr" rid="bib38">Poulikakos et al., 2010</xref>; <xref ref-type="bibr" rid="bib22">Karoulia et al., 2016</xref>; <xref ref-type="bibr" rid="bib57">Yen et al., 2021</xref>; <xref ref-type="bibr" rid="bib7">Cotto-Rios et al., 2020</xref>; <xref ref-type="bibr" rid="bib25">Lai et al., 2022</xref>; <xref ref-type="bibr" rid="bib26">Lavoie et al., 2013</xref>), and demonstrated to trigger expression of ERK target genes and increased cell proliferation (<xref ref-type="bibr" rid="bib25">Lai et al., 2022</xref>). We along with others show that ponatinib can activate ERK in RAS-mutant cells at concentrations as low as 1 nM, and that this activation is only suppressed at concentrations above 1 Î¼M (<xref ref-type="bibr" rid="bib7">Cotto-Rios et al., 2020</xref>), higher than the plasma level achievable in patients (<xref ref-type="bibr" rid="bib56">Ye et al., 2017</xref>). Similarly, while belvarafenib has shown promising activity in preclinical and clinical studies (<xref ref-type="bibr" rid="bib57">Yen et al., 2021</xref>), it increases MAPK signaling over a concentration range similar to other type II inhibitors like LY3009120, which has shown an unexpected lack of clinical efficacy (<xref ref-type="bibr" rid="bib46">Sullivan et al., 2020</xref>) despite favorable preclinical results (<xref ref-type="bibr" rid="bib37">Peng et al., 2015</xref>; <xref ref-type="bibr" rid="bib57">Yen et al., 2021</xref>; <xref ref-type="bibr" rid="bib5">Chen et al., 2016</xref>). Ultimately, whether paradoxical activation contributes to clinical outcomes for a particular inhibitor may depend on where the achievable dose lies with respect to the activation and inhibition sides of the paradoxical activation curves.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Protein expression and purification</title><p>Human BRAF kinase domain (residues 448â723 with a tobacco etch virus [TEV]-protease-cleavable N-terminal 6x-His tag in pProEX) containing 16 mutations to improve solubility (<xref ref-type="bibr" rid="bib50">Tsai et al., 2008</xref>) was expressed in chemically competent BL21 (DE3) RIL <italic>Escherichia coli</italic> (Agilent) for 18 hr at 18Â°C. Following sonication (Qsonica), lysates were clarified by centrifugation and loaded onto a HisTrap HP column (Cytiva). The column was washed with lysis buffer (50 mM Tris pH 8.0, 500 mM NaCl, 10% glycerol, 25 mM imidazole) and eluted with a 0â50% imidazole gradient over 12 column volumes using elution buffer (50 mM Tris pH 8.0, 500 mM NaCl, 10% glycerol, 500 mM imidazole). The His tag was cleaved overnight at 4Â°C with TEV protease. TEV protease was removed by an additional pass over a HisTrap HP column. Protein was further purified and desalted into desalt buffer (25 mM HEPES pH 7.5, 10% glycerol, 300 mM NaCl) using a Superdex S75 10/300 GL size exclusion column (Cytiva). Expression levels of BRAF mutants were increased by adding an N-terminal SUMO tag to the expression construct.</p><p>Human MEK1 kinase domain (residues 1â393 with a TEV-protease-cleavable N-terminal 6x-His tag in pET-Duet) containing an inactivating K97R mutation was expressed in chemically competent BL21 (DE3) RIL <italic>E. coli</italic> (Agilent) for 18 hr at 18Â°C. Cell pellets were sonicated in MEK lysis buffer (25 mM HEPES pH 7.5, 500 mM NaCl, 10% glycerol, 10 mM BME, 1 mM PMSF, 1Ã EDTA-free protease inhibitors [Roche], 20 mM imidazole) and clarified by centrifugation. Lysate was loaded onto a HisTrap HP column (Cytiva) and washed with MEK lysis buffer before eluting with a 0â50% imidazole gradient over 12 column volumes using elution buffer (25 mM HEPES pH 7.5, 500 mM NaCl, 10% glycerol, 10 mM BME, 300 mM imidazole). The His tag was cleaved overnight at 4Â°C with TEV protease. TEV protease was removed by an additional pass over the HisTrap HP column. Protein was further purified and desalted into desalt buffer (25 mM HEPES pH 7.5, 10% glycerol, 150 mM NaCl) using a Superdex S75 10/300 GL size exclusion column (Cytiva).</p></sec><sec id="s4-2"><title>FRET experiments tracking BRAF dimerization</title><p>We used the K547C site on the Î±D/Î±E-loop of BRAF to incorporate FRET dyes (<xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1a</xref>). BRAF FRET samples were prepared by covalently labeling two separate pools of BRAF at 25 Î¼M on K547C with either donor (Alexa Fluor 488 C<sub>5</sub> maleimide, Thermo Fisher) or acceptor (Alexa Fluor 568 C<sub>5</sub> maleimide, Thermo Fisher) at 0.8:1 molar ratio of fluorophore to protein, on ice. Labeling reactions were quenched at 1 hr with 1 mM DTT. Stopped flow fluorescence anisotropy experiments showed that the labeling kinetics of BRAF<sup>K547C</sup> were approximately 2 orders of magnitude faster than those of BRAF (<xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1b</xref>), indicating that the K547C site can be selectively labeled without removing endogenous cysteines (C532, C685, C696). Mass spectrometry was used to confirm that only one cysteine was labeled with only one donor or acceptor fluorophore (<xref ref-type="fig" rid="fig4s2">Figure 4âfigure supplement 2a</xref>). Donor-labeled and acceptor-labeled BRAF were then mixed at equal molar ratios and diluted into FRET buffer (25 mM HEPES pH 7.5, 300 mM NaCl, 10% glycerol, 10 mM MgCl<sub>2</sub>, 1 mM EGTA, 2% DMSO). BRAF FRET sensor (49 Î¼L) was then added to 384-well inhibitor titration plates containing 1 Î¼L of inhibitor in DMSO prepared using a mosquito liquid handling robot (ttp Labtech) and incubated at room temperature for 90 min to ensure the reactions were at equilibrium. Dimerization experiments consisted of inhibitor titrations containing 12 concentrations including a DMSO-only control. Experiments for each inhibitor were done in duplicate at six different BRAF concentrations. Fluorescence data were recorded with a custom-built fluorescence plate reader (<xref ref-type="bibr" rid="bib44">Schaaf et al., 2017</xref>) (Fluorescence Innovations) and contributions from the donor and acceptor fluorescence emission intensities (FRET A/D) were quantified by spectral unmixing using three basis functions for AF488 emission, AF568 emission, and Raman scattering (<xref ref-type="bibr" rid="bib44">Schaaf et al., 2017</xref>).</p></sec><sec id="s4-3"><title>Global fitting analysis and thermodynamic modeling of FRET data</title><p>FRET A/D values were globally fit to a thermodynamic model describing inhibitor-induced BRAF dimerization (<xref ref-type="bibr" rid="bib23">Kholodenko, 2015</xref>) shown in <xref ref-type="fig" rid="fig1">Figure 1c</xref> using the fitting and simulation software KinTek Explorer (<ext-link ext-link-type="uri" xlink:href="https://kintekcorp.com/software">https://kintekcorp.com/software</ext-link>; <xref ref-type="bibr" rid="bib20">Johnson et al., 2009</xref>). In this model B and D represent monomeric BRAF and drug/inhibitor, respectively, and B, BB, BBD, BBDD represent apo monomeric BRAF, apo dimeric BRAF, dimeric BRAF partially occupied with one inhibitor molecule, and dimeric BRAF fully saturated with two inhibitor molecules. The equilibrium dissociation constants K<sub>D</sub><sup>dimer</sup> and K<sub>D</sub><sup>drug</sup> describe apo BRAF dimerization and inhibitor binding to monomeric BRAF, respectively. Microscopic reversibility restricts the specific values and relationships between each equilibrium constant within a cyclic path, such that the product of equilibrium constants along a cycle must equal one (<xref ref-type="bibr" rid="bib23">Kholodenko, 2015</xref>; <xref ref-type="bibr" rid="bib10">Ederer and Gilles, 2007</xref>). Consequently, each reaction within the model can be described in terms of either K<sub>D</sub><sup>dimer</sup> or K<sub>D</sub><sup>drug</sup> together with the allosteric coupling parameters Î± and Î², which quantify the allosteric coupling in the system as described in the main text.</p><table-wrap id="inlinetable1" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reaction</th><th align="left" valign="bottom">Equilibrium dissociation constant</th><th align="left" valign="bottom">Definition of thermodynamic factors</th></tr></thead><tbody><tr><td align="left" valign="bottom">B+BâBB</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf20"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi mathvariant="normal">K</mml:mi><mml:mrow><mml:mi mathvariant="normal">D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">B+DâBD</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf21"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi mathvariant="normal">K</mml:mi><mml:mrow><mml:mi mathvariant="normal">D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">BB +DâBBD</td><td align="left" valign="bottom">K<sub>3</sub> = <inline-formula><mml:math id="inf22"><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>Î±</mml:mi></mml:mrow></mml:mfrac></mml:math></inline-formula> Â· <inline-formula><mml:math id="inf23"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi mathvariant="normal">K</mml:mi><mml:mrow><mml:mi mathvariant="normal">D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf24"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>2</mml:mn><mml:mi>Î±</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:msubsup><mml:mi mathvariant="normal">K</mml:mi><mml:mrow><mml:mi mathvariant="normal">D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mi mathvariant="normal">K</mml:mi><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula></td></tr><tr><td align="left" valign="bottom">BD +BâBBD</td><td align="left" valign="bottom">K<sub>4</sub> = <inline-formula><mml:math id="inf25"><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>Î±</mml:mi></mml:mrow></mml:mfrac></mml:math></inline-formula> Â· <inline-formula><mml:math id="inf26"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi mathvariant="normal">K</mml:mi><mml:mrow><mml:mi mathvariant="normal">D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf27"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>2</mml:mn><mml:mi>Î±</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:msubsup><mml:mi mathvariant="normal">K</mml:mi><mml:mrow><mml:mi mathvariant="normal">D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mi mathvariant="normal">K</mml:mi><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula></td></tr><tr><td align="left" valign="bottom">BD +BDâBBDD</td><td align="left" valign="bottom">K<sub>5</sub> = <inline-formula><mml:math id="inf28"><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>Î±</mml:mi><mml:mi>Î²</mml:mi></mml:mrow></mml:mfrac></mml:math></inline-formula> Â· <inline-formula><mml:math id="inf29"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi mathvariant="normal">K</mml:mi><mml:mrow><mml:mi mathvariant="normal">D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf30"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>Î²</mml:mi><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mn>2</mml:mn><mml:mo>=</mml:mo><mml:mfrac><mml:msub><mml:mi mathvariant="normal">K</mml:mi><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi mathvariant="normal">K</mml:mi><mml:mrow><mml:mn>5</mml:mn></mml:mrow></mml:msub></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula></td></tr><tr><td align="left" valign="bottom">BBD +DâBBDD</td><td align="left" valign="bottom">K<sub>6</sub> = <inline-formula><mml:math id="inf31"><mml:mfrac><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>Î²</mml:mi></mml:mrow></mml:mfrac></mml:math></inline-formula> Â· <inline-formula><mml:math id="inf32"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi mathvariant="normal">K</mml:mi><mml:mrow><mml:mi mathvariant="normal">D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf33"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>Î²</mml:mi><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mn>2</mml:mn><mml:mo>=</mml:mo><mml:mfrac><mml:msubsup><mml:mi mathvariant="normal">K</mml:mi><mml:mrow><mml:mi mathvariant="normal">D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mi mathvariant="normal">K</mml:mi><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula></td></tr></tbody></table></table-wrap><p>The factor of two in the above definitions arises from the stoichiometry of the reactions and the presence of two inhibitor binding sites within the BRAF dimer (<xref ref-type="bibr" rid="bib23">Kholodenko, 2015</xref>).</p><p>The FRET A/D values were mapped onto the thermodynamic model using one fluorescence coefficient (C1) to describe monomeric and low-FRET forms of BRAF in solution (B, BD), and one fluorescence coefficient (C2) to describe dimeric high-FRET forms of BRAF in solution (BB, BBD, BBDD).<disp-formula id="equ1"><mml:math id="m1"><mml:mrow><mml:mfrac><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">D</mml:mi></mml:mfrac><mml:mo>=</mml:mo><mml:mi mathvariant="normal">C</mml:mi><mml:mn>1</mml:mn><mml:mo>Ã</mml:mo><mml:mfrac><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi mathvariant="normal">B</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">D</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi mathvariant="normal">B</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">B</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">D</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mi mathvariant="normal">C</mml:mi><mml:mn>2</mml:mn><mml:mo>Ã</mml:mo><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">B</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">D</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi mathvariant="normal">B</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">B</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">D</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula></p><p>All experiments were fit to this model with the equilibrium dissociation constants K<sub>D</sub><sup>dimer</sup>, K<sub>D</sub><sup>drug</sup>, <inline-formula><mml:math id="inf34"><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>Î±</mml:mi></mml:mrow></mml:mfrac></mml:math></inline-formula>K<sub>D</sub><sup>dimer</sup>, <inline-formula><mml:math id="inf35"><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>Î±</mml:mi><mml:mi>Î²</mml:mi></mml:mrow></mml:mfrac></mml:math></inline-formula>K<sub>D</sub><sup>dimer</sup>, <inline-formula><mml:math id="inf36"><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>Î±</mml:mi></mml:mrow></mml:mfrac></mml:math></inline-formula>K<sub>D</sub><sup>drug</sup>, <inline-formula><mml:math id="inf37"><mml:mfrac><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>Î²</mml:mi></mml:mrow></mml:mfrac></mml:math></inline-formula>K<sub>D</sub><sup>drug</sup> defined by k<sub>-1</sub>/k<sub>1</sub>=K<sub>D</sub>. The equilibrium dissociation constants were allowed to float in global fitting by locking the association rate constant to an arbitrarily high value beyond the diffusion limit (k<sub>1</sub>=1000 nM<sup>â1</sup> s<sup>â1</sup>) and allowing k<sub>-1</sub> to vary as described in the KinTek Explorer manual. The dimerization affinity of apo BRAF (K<sub>D</sub><sup>dimer</sup>) was determined to be 62.4Â±2.9 Î¼M in separate experiments using high concentrations of BRAF to maximize the dimerization signal (<xref ref-type="fig" rid="fig1s2">Figure 1âfigure supplement 2</xref>). This value was then used to constrain K<sub>D</sub><sup>dimer</sup> in the fitting of other datasets, allowing lower concentrations of BRAF to be used. For BRAF concentrations above 2 Î¼M an additional linear scale factor accounting for the secondary inner filter effect was required to fit the data. In the initial round of global fitting, the BRAF concentrations in the model, [BRAF]<sub>1-6</sub>, were locked to their experimentally determined values. This fitting procedure yielded strongly asymmetric allosteric models for the type II inhibitors, and more symmetric models for the type I inhibitors. All parameters were constrained in these fits as determined by one-dimensional (1D) error surface analysis using chi2 thresholds calculated as previously described (<xref ref-type="fig" rid="fig1s4">Figure 1âfigure supplement 4a and b</xref>; <xref ref-type="bibr" rid="bib20">Johnson et al., 2009</xref>). Two-dimensional (2D) error surface analysis further confirmed that the pairs of equilibrium constants from which the Î± and Î² values are derived (e.g. K<sub>D</sub><sup>dimer</sup> and <inline-formula><mml:math id="inf38"><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>Î±</mml:mi></mml:mrow></mml:mfrac></mml:math></inline-formula>K<sub>D</sub><sup>dimer</sup>) are well constrained with respect to one another (<xref ref-type="fig" rid="fig1s4">Figure 1âfigure supplement 4c</xref>). To investigate the effects of errors in protein concentration, a second round of global fitting was performed in which the [BRAF]<sub>1-6</sub> values were included as floating parameters in the fit, and 1D and 2D error surfaces used to confirm that the fits remained constrained despite the increased number of parameters (<xref ref-type="fig" rid="fig1s2">Figure 1âfigure supplements 2</xref> and <xref ref-type="fig" rid="fig1s4">4d</xref>). For a subset of type II datasets, this procedure led to the appearance of double minima in the error surfaces, with one minimum corresponding to a highly asymmetric model and the other to a more symmetric model (<xref ref-type="fig" rid="fig1s11">Figure 1âfigure supplement 11</xref>). To verify that the asymmetric models correspond to the correct solution, as indicated by the first round of fitting, inhibitor-induced BBD induction was simulated using the parameter values associated with both alternative models (<xref ref-type="fig" rid="fig1s11">Figure 1âfigure supplement 11b</xref>) and compared to independently measured inhibitor-induced kinase activity (<xref ref-type="fig" rid="fig1s11">Figure 1âfigure supplement 11c</xref>) to calculate a putative turnover number for the BBD dimer for each model solution (<xref ref-type="fig" rid="fig1s11">Figure 1âfigure supplement 11d</xref>). Comparison with the catalytic turnover reported for 14-3-3-bound BRAF dimers (<xref ref-type="bibr" rid="bib29">Liau et al., 2020</xref>; <xref ref-type="fig" rid="fig1s11">Figure 1âfigure supplement 11d</xref>) showed that the asymmetric models were consistent with these published data (slightly lower activity than fully active BRAF dimers consistent with partial inhibition), whereas the symmetric models would require unrealistically high kinase activity for the BBD dimer (fivefold higher activity than fully active BRAF dimers despite partial inhibition). The results reported in the manuscript correspond to the values from the second round of global fitting.</p></sec><sec id="s4-4"><title>In vitro kinase activity assays</title><p>Kinase activity of BRAF K547C was measured using the FRET-based LanthaScreen kinase activity assay (Thermo Fisher). Kinase dead MEK1 K97R was labeled at 40 Î¼M with Alexa Fluor 488 C<sub>5</sub> maleimide at a 1:1 molar ratio on ice for 1 hr. The labeling reaction was quenched using 1 mM DTT and desalted into 25 mM HEPES pH 7.5, 10% glycerol, and 150 mM NaCl. BRAF<sup>15m</sup> (BRAF<sup>16m</sup> with the additional E667F reversion mutation that restores MEK binding) was incubated at 400 nM with 2 Î¼M MEK and 2Ã kinase buffer (50 mM HEPES pH 7.5, 0.2 mg/mL bovine Î³-globulins, 20 mM MgCl<sub>2</sub>, 600 mM NaCl, 2 mM EGTA) for 15 min. Inhibitor (1 Î¼L) in 50% DMSO was then added to the BRAF/MEK reaction and incubated at room temperature for 1 hr. The kinase reaction was then initiated with the addition of 250 Î¼M ATP for a final reaction concentration of 200 nM BRAF, 1 Î¼M MEK, 100 Î¼M ATP, 1Ã kinase buffer, and 5% DMSO with inhibitor and incubated for 60 min. Reactions were quenched with a 2Ã dilution into TR-FRET buffer (Thermo Fisher) with 40 mM EDTA and 4 nM LanthaScreen Tb-pMAP2K1 (pSer 217/pSer 221) antibody (Thermo Fisher) and incubated at room temperature for 2 hr. The TR-FRET ratio was measured using a Tecan M1000 pro plate reader with excitation at 340 nm followed by a 100 Î¼s delay before reading emission at 490 nm (donor) and 520 nm (acceptor) with a 200 Î¼s integration time. Increases in kinase activity were inferred from increases in FRET (A/D ratio). Kinase turnover (s<sup>â1</sup>) was interpolated from a phoshoMEK1 standard curve. Outliers were identified and removed from analysis using the ROUT method in GraphPad Prism with a recommended Q coefficient of 1%.</p></sec><sec id="s4-5"><title>Flow cytometry</title><p>SK-MEL-2 melanoma cells (purchased from ATCC and used directly for experiments) were seeded into 96-well V-bottom plates at 1Ã10<sup>7</sup> cells/mL in 100 ÂµL Dulbeccoâs Modified Eagle Medium (Corning) supplemented with 100 U/mL penicillin-streptomycin and 10% FBS. Cells were rested for 1 hr and treated for 1 hr at 37Â°C with RAF inhibitor or DMSO (vehicle) to a final concentration of 0.1% DMSO. Cells were then fixed in 4% paraformaldehyde for 20 min at 4Â°C. Cells were then washed twice in FACS buffer (PBS, 2% FBS, 2 mM EDTA) and permeabilized in BD Phosflow Perm Buffer III (BD Biosciences), according to the manufacturerâs instructions. Cells were then stained in FACS buffer with anti-pMEK1/2 (BD Biosciences) and anti-pERK1/2 (BD Biosciences). After washing, samples were analyzed on a BD Fortessa X-30 flow cytometer. Using FlowJo software (TreeStar), live, single cells were selected for further analysis (gated) via characteristic laser side scatter (SSC, 90Â°) vs. forward scatter (FSC, in-path) area and magnitude profiles. Gates quantifying the frequency of maximally signaling pMEK<sup>hi</sup>/pERK<sup>hi</sup> cells within this population were placed using a quadrant with an arbitrary cutoff of 15% for each vehicle control. Gate positions were then copied to other samples for identical positioning across inhibitor concentrations within the same staining panel and experiment day. Data were analyzed in Prism (GraphPad), with significance assessed by one-way ANOVA with Tukeyâs correction for multiple comparisons, with pMEK<sup>hi</sup>/pERK<sup>hi</sup> cell frequencies compared to all other inhibitor doses within each inhibitor titration.</p></sec><sec id="s4-6"><title>Immunoblotting</title><p>Immunoblotting was performed as previously described (<xref ref-type="bibr" rid="bib2">Brian et al., 2022</xref>; <xref ref-type="bibr" rid="bib1">Brian et al., 2020</xref>). Briefly, 0.025 million cell equivalents of whole cell lysate were run through 7% Tris-acetate polyacrylamide gels and transferred to polyvinylidene difluoride membranes. Membranes were blocked in Intercept (TBS) Blocking Buffer (LI-COR Biosciences) for 1 hr, and then incubated overnight with primary antibody: ARAF (Cell Signaling), BRAF (Cell Signaling), CRAF (Cell Signaling), MEK1/2 (Cell Signaling), and ERK1/2 (Cell Signaling). Membranes were washed and incubated for 1 hr at room temperature with corresponding species-reactive secondary antibody and then imaged using an Odyssey CLx near-infrared imager (LI-COR Biosciences).</p></sec><sec id="s4-7"><title>DEER spectroscopy</title><p>DEER samples were prepared by labeling 10 Î¼M BRAF containing three dimer-breaking mutations (BRAF<sup>DB</sup>,R509H, L515G, M517W) (<xref ref-type="bibr" rid="bib42">RÃ¶ring et al., 2012</xref>) on the Î±C-helix (Q493C) and the Î±G-helix (Q664C) with a twofold excess of 4-maleimido-TEMPO for 45 min at 4Â°C. Spin-labeled BRAF was concentrated to 60â80 Î¼M, buffered in D<sub>2</sub>O with 25 mM HEPES pH 7.5, 500 mM NaCl, and 10% d<sub>8</sub>-glycerol and rapidly frozen in 1.1 mm ID/1.6 mm OD quartz capillary tubes using liquid nitrogen-cooled isopropanol. For samples containing inhibitors, prior to freezing, BRAF was incubated for 90 min with a fivefold molar excess of inhibitor dissolved in deuterated DMSO. DEER spectra were collected at 65 K on an Elexsys E580 spectrometer (Bruker) equipped with an EN5107 resonator operating at Q-band frequencies using parameters previously described (<xref ref-type="bibr" rid="bib30">Majumdar et al., 2021</xref>) Data were analyzed using custom software (<ext-link ext-link-type="uri" xlink:href="https://github.com/thompsar/Venison">https://github.com/thompsar/Venison</ext-link>, copy archived at <xref ref-type="bibr" rid="bib48">Thompson, 2022</xref>) written in Python and based on DeerAnalysis 2017. DEER data were phased and background-corrected using a homogeneous background model to derive the DEER waveform. Distance distributions were obtained by fitting these waveforms using unconstrained Tikhonov regularization, with smoothing parameter Î» chosen using the L-curve method and leave-one-out cross-validation. Features of the DEER waveform that contributed to unstable populations that were distinct from the primary populations and beyond the sensitivity limit of the 6 Âµs evolution time (~60 Ã) were suppressed by incorporation into the background model. The distribution obtained by Tikhonov regularization using this corrected waveform was used to initialize fitting of the waveforms to a sum of Gaussians model that describes the centers of the spin-spin distances, as well as the widths and mole fractions. The number of subpopulations was determined by selecting the fewest number of Gaussian centers that met the RMSD minimization threshold calculated by the Bayesian information criterion. Distance distributions were in good agreement with distributions calculated from X-ray structures of the Î±C-in and Î±C-out states using MtsslSuite (<ext-link ext-link-type="uri" xlink:href="http://www.mtsslsuite.isb.ukbonn.de/">http://www.mtsslsuite.isb.ukbonn.de/</ext-link>; <xref ref-type="bibr" rid="bib12">Hagelueken et al., 2012</xref>).</p></sec><sec id="s4-8"><title><sup>19</sup>F NMR spectroscopy</title><p>BRAF <sup>19</sup>F samples were prepared by covalently labeling 50 Î¼M of BRAF<sup>16m</sup> on a single Î±C-helix cysteine (Q493C) with a 1.75 molar excess of BTFA for 1 hr at 4Â°C. Samples were quenched with 1 mM DTT and desalted into NMR buffer (25 mM HEPES pH 7.5, 500 mM NaCl, 10% glycerol) supplemented with 10% D<sub>2</sub>O and 0.005% trifluoroacetic acid as an internal reference. The presence of only one BTFA probe on the BRAF kinase domain was verified by mass spectrometry (<xref ref-type="fig" rid="fig4s2">Figure 4âfigure supplement 2a</xref>). Circular dichroism temperature denaturation experiments were carried out to verify that the BTFA probe did not alter BRAF stability at the temperatures used in NMR experiments (<xref ref-type="fig" rid="fig4s2">Figure 4âfigure supplement 2b</xref>). <sup>19</sup>F NMR experiments were performed at 298 K using a Bruker 600 MHz Avance NEO equipped with a 5 mm cryogenic triple resonance probe tuned to 565.123 MHz. 1D spectra were collected using the zg pulse program (Bruker TopSpin 4.1.4) with a 13.5 Î¼s 90Â° pulse time, 0.2 s acquisition time, and a 1 s D1 relaxation delay time. Variable-temperature experiments involved a 5 min sample equilibration period at each temperature prior to collecting spectra. Transverse relaxation (T<sub>2</sub>) experiments were performed using the Carr-Purcell-Meiboom-Gill pulse sequence with a 12 Î¼s 90Â° pulse time, 2 s D1 relaxation delay, 200 Î¼s D<sub>2</sub>O fixed spin-echo time, and a 24 Î¼s 180Â° refocusing period. Spectra were acquired with 2048 scans with total transverse magnetization times of 0.4, 1.6, 2.4, 3.2, 6.4, 12.8, 25.6, 51.2, and 102.4 ms. 1D spectra were processed using MestReNova 14.3.0 by aligning the TFA reference to â75.32 ppm, applying automatic zeroth- and first-order phase corrections, a 3Â° polynomial Bernstein baseline correction, and 1 Hz line broadening correction.</p><p>T<sub>2</sub> relaxation profiles were created by measuring the intensity at â84.42 ppm (Î±C-out) and â84.29 ppm (Î±C-in) as a function of delay time and fit to both single and double exponential decay models in GraphPad Prism 9.4.0 with the double exponential being the preferred model for both resonances as determined by an extra sum-of-squares F-test (pË0.0001). In a separate T<sub>2</sub> analysis, each spectrum was subjected to spectral deconvolution using OriginPro 2022 by fitting the 1D spectra to a three-component Lorentzian model. The time dependence of the component amplitudes is shown in <xref ref-type="fig" rid="fig4">Figure 4b</xref>.</p></sec><sec id="s4-9"><title>Mass spectrometry analysis of commercial kinase inhibitors</title><p>Commercially available RAF kinase inhibitors were purchased from Selleckchem and TargetMol. High-resolution mass spectrometry data were collected on a Bruker BioTOF II instrument with an infusion electrospray ionizer. Compounds were dissolved in DMSO to a concentration of 10 mM. Stocks were diluted 100Ã with MeOH and injected at a rate of 10 ÂµL/min. Mass spectrometry was run and analyzed in positive-ion mode with either a PEG 600 or PEG 400 internal standard (see <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Data were analyzed using Bruker Data Analysis Software.</p></sec><sec id="s4-10"><title>Code availability</title><p>The program used to analyze DEER data for this study, Venison, is available for download from <ext-link ext-link-type="uri" xlink:href="https://github.com/thompsar/Venison">https://github.com/thompsar/Venison</ext-link>, (copy archived at <xref ref-type="bibr" rid="bib48">Thompson, 2022</xref>).</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Validation, Visualization, Methodology, Writing â original draft, Writing â review and editing, Formal analysis, Funding acquisition, Investigation</p></fn><fn fn-type="con" id="con2"><p>Investigation, Visualization, Methodology, Formal analysis</p></fn><fn fn-type="con" id="con3"><p>Investigation, Visualization, Methodology, Formal analysis</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Software, Validation</p></fn><fn fn-type="con" id="con5"><p>Software, Validation, Investigation, Methodology</p></fn><fn fn-type="con" id="con6"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con7"><p>Validation, Methodology</p></fn><fn fn-type="con" id="con8"><p>Validation, Investigation, Methodology</p></fn><fn fn-type="con" id="con9"><p>Validation, Investigation, Visualization, Methodology, Writing â review and editing</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Resources, Data curation, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Project administration, Writing â review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Inhibitor sources and validation by mass spectrometry.</title></caption><media xlink:href="elife-95481-supp1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All source data are available in this paper and supplementary information. The program used to analyze DEER data for this study, Venison, is available for download from <ext-link ext-link-type="uri" xlink:href="https://github.com/thompsar/Venison">https://github.com/thompsar/Venison</ext-link>, copy archived at <xref ref-type="bibr" rid="bib48">Thompson, 2022</xref>.</p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Frank Sicheri and Scott Prosser for insightful conversations, Frank Sicheri for the BRAF<sup>16m</sup> construct, and Donita Brady for the human MEK construct. We thank Todd Rappe for help with NMR experiments, Joseph Dalluge for help with mass spectrometry, and Jaclyn Frank for assistance with manuscript preparation. DMR acknowledges support from F31CA257218 and T32GM132029, JTG acknowledges support from American Cancer Society â Kirby Foundation Postdoctoral Fellowship PF-21-068-01-LIB, TSF acknowledges support from R01AR073966, NML acknowledges support from R33CA246363, and WCKP acknowledges support from 5R35GM140837.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brian</surname><given-names>BF</given-names></name><name><surname>Guerrero</surname><given-names>CR</given-names></name><name><surname>Freedman</surname><given-names>TS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Immunopharmacology and quantitative analysis of tyrosine kinase signaling</article-title><source>Current Protocols in Immunology</source><volume>130</volume><elocation-id>e104</elocation-id><pub-id pub-id-type="doi">10.1002/cpim.104</pub-id><pub-id pub-id-type="pmid">32931655</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brian</surname><given-names>BF</given-names></name><name><surname>Sauer</surname><given-names>ML</given-names></name><name><surname>Greene</surname><given-names>JT</given-names></name><name><surname>Senevirathne</surname><given-names>SE</given-names></name><name><surname>Lindstedt</surname><given-names>AJ</given-names></name><name><surname>Funk</surname><given-names>OL</given-names></name><name><surname>Ruis</surname><given-names>BL</given-names></name><name><surname>Ramirez</surname><given-names>LA</given-names></name><name><surname>Auger</surname><given-names>JL</given-names></name><name><surname>Swanson</surname><given-names>WL</given-names></name><name><surname>Nunez</surname><given-names>MG</given-names></name><name><surname>Moriarity</surname><given-names>BS</given-names></name><name><surname>Lowell</surname><given-names>CA</given-names></name><name><surname>Binstadt</surname><given-names>BA</given-names></name><name><surname>Freedman</surname><given-names>TS</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>A dominant function of LynB kinase in preventing autoimmunity</article-title><source>Science Advances</source><volume>8</volume><elocation-id>eabj5227</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.abj5227</pub-id><pub-id pub-id-type="pmid">35452291</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brummer</surname><given-names>T</given-names></name><name><surname>McInnes</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>RAF kinase dimerization: implications for drug discovery and clinical outcomes</article-title><source>Oncogene</source><volume>39</volume><fpage>4155</fpage><lpage>4169</lpage><pub-id pub-id-type="doi">10.1038/s41388-020-1263-y</pub-id><pub-id pub-id-type="pmid">32269299</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chapman</surname><given-names>PB</given-names></name><name><surname>Hauschild</surname><given-names>A</given-names></name><name><surname>Robert</surname><given-names>C</given-names></name><name><surname>Haanen</surname><given-names>JB</given-names></name><name><surname>Ascierto</surname><given-names>P</given-names></name><name><surname>Larkin</surname><given-names>J</given-names></name><name><surname>Dummer</surname><given-names>R</given-names></name><name><surname>Garbe</surname><given-names>C</given-names></name><name><surname>Testori</surname><given-names>A</given-names></name><name><surname>Maio</surname><given-names>M</given-names></name><name><surname>Hogg</surname><given-names>D</given-names></name><name><surname>Lorigan</surname><given-names>P</given-names></name><name><surname>Lebbe</surname><given-names>C</given-names></name><name><surname>Jouary</surname><given-names>T</given-names></name><name><surname>Schadendorf</surname><given-names>D</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>OâDay</surname><given-names>SJ</given-names></name><name><surname>Sosman</surname><given-names>JA</given-names></name><name><surname>Kirkwood</surname><given-names>JM</given-names></name><name><surname>Eggermont</surname><given-names>AMM</given-names></name><name><surname>Dreno</surname><given-names>B</given-names></name><name><surname>Nolop</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Nelson</surname><given-names>B</given-names></name><name><surname>Hou</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>RJ</given-names></name><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>McArthur</surname><given-names>GA</given-names></name><collab>BRIM-3 Study Group</collab></person-group><year iso-8601-date="2011">2011</year><article-title>Improved survival with vemurafenib in melanoma with BRAF V600E mutation</article-title><source>The New England Journal of Medicine</source><volume>364</volume><fpage>2507</fpage><lpage>2516</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1103782</pub-id><pub-id pub-id-type="pmid">21639808</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>SH</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Van Horn</surname><given-names>RD</given-names></name><name><surname>Yin</surname><given-names>T</given-names></name><name><surname>Buchanan</surname><given-names>S</given-names></name><name><surname>Yadav</surname><given-names>V</given-names></name><name><surname>Mochalkin</surname><given-names>I</given-names></name><name><surname>Wong</surname><given-names>SS</given-names></name><name><surname>Yue</surname><given-names>YG</given-names></name><name><surname>Huber</surname><given-names>L</given-names></name><name><surname>Conti</surname><given-names>I</given-names></name><name><surname>Henry</surname><given-names>JR</given-names></name><name><surname>Starling</surname><given-names>JJ</given-names></name><name><surname>Plowman</surname><given-names>GD</given-names></name><name><surname>Peng</surname><given-names>SB</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Oncogenic BRAF deletions that function as homodimers and are sensitive to inhibition by RAF dimer inhibitor LY3009120</article-title><source>Cancer Discovery</source><volume>6</volume><fpage>300</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-15-0896</pub-id><pub-id pub-id-type="pmid">26732095</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>FA</given-names></name><name><surname>Cook</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Inhibition of RAF dimers: it takes two to tango</article-title><source>Biochemical Society Transactions</source><volume>49</volume><fpage>237</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1042/BST20200485</pub-id><pub-id pub-id-type="pmid">33367512</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cotto-Rios</surname><given-names>XM</given-names></name><name><surname>Agianian</surname><given-names>B</given-names></name><name><surname>Gitego</surname><given-names>N</given-names></name><name><surname>Zacharioudakis</surname><given-names>E</given-names></name><name><surname>Giricz</surname><given-names>O</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Zou</surname><given-names>Y</given-names></name><name><surname>Verma</surname><given-names>A</given-names></name><name><surname>Poulikakos</surname><given-names>PI</given-names></name><name><surname>Gavathiotis</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Inhibitors of BRAF dimers using an allosteric site</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>4370</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-18123-2</pub-id><pub-id pub-id-type="pmid">32873792</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>H</given-names></name><name><surname>Bignell</surname><given-names>GR</given-names></name><name><surname>Cox</surname><given-names>C</given-names></name><name><surname>Stephens</surname><given-names>P</given-names></name><name><surname>Edkins</surname><given-names>S</given-names></name><name><surname>Clegg</surname><given-names>S</given-names></name><name><surname>Teague</surname><given-names>J</given-names></name><name><surname>Woffendin</surname><given-names>H</given-names></name><name><surname>Garnett</surname><given-names>MJ</given-names></name><name><surname>Bottomley</surname><given-names>W</given-names></name><name><surname>Davis</surname><given-names>N</given-names></name><name><surname>Dicks</surname><given-names>E</given-names></name><name><surname>Ewing</surname><given-names>R</given-names></name><name><surname>Floyd</surname><given-names>Y</given-names></name><name><surname>Gray</surname><given-names>K</given-names></name><name><surname>Hall</surname><given-names>S</given-names></name><name><surname>Hawes</surname><given-names>R</given-names></name><name><surname>Hughes</surname><given-names>J</given-names></name><name><surname>Kosmidou</surname><given-names>V</given-names></name><name><surname>Menzies</surname><given-names>A</given-names></name><name><surname>Mould</surname><given-names>C</given-names></name><name><surname>Parker</surname><given-names>A</given-names></name><name><surname>Stevens</surname><given-names>C</given-names></name><name><surname>Watt</surname><given-names>S</given-names></name><name><surname>Hooper</surname><given-names>S</given-names></name><name><surname>Wilson</surname><given-names>R</given-names></name><name><surname>Jayatilake</surname><given-names>H</given-names></name><name><surname>Gusterson</surname><given-names>BA</given-names></name><name><surname>Cooper</surname><given-names>C</given-names></name><name><surname>Shipley</surname><given-names>J</given-names></name><name><surname>Hargrave</surname><given-names>D</given-names></name><name><surname>Pritchard-Jones</surname><given-names>K</given-names></name><name><surname>Maitland</surname><given-names>N</given-names></name><name><surname>Chenevix-Trench</surname><given-names>G</given-names></name><name><surname>Riggins</surname><given-names>GJ</given-names></name><name><surname>Bigner</surname><given-names>DD</given-names></name><name><surname>Palmieri</surname><given-names>G</given-names></name><name><surname>Cossu</surname><given-names>A</given-names></name><name><surname>Flanagan</surname><given-names>A</given-names></name><name><surname>Nicholson</surname><given-names>A</given-names></name><name><surname>Ho</surname><given-names>JWC</given-names></name><name><surname>Leung</surname><given-names>SY</given-names></name><name><surname>Yuen</surname><given-names>ST</given-names></name><name><surname>Weber</surname><given-names>BL</given-names></name><name><surname>Seigler</surname><given-names>HF</given-names></name><name><surname>Darrow</surname><given-names>TL</given-names></name><name><surname>Paterson</surname><given-names>H</given-names></name><name><surname>Marais</surname><given-names>R</given-names></name><name><surname>Marshall</surname><given-names>CJ</given-names></name><name><surname>Wooster</surname><given-names>R</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Mutations of the BRAF gene in human cancer</article-title><source>Nature</source><volume>417</volume><fpage>949</fpage><lpage>954</lpage><pub-id pub-id-type="doi">10.1038/nature00766</pub-id><pub-id pub-id-type="pmid">12068308</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dummer</surname><given-names>R</given-names></name><name><surname>Ascierto</surname><given-names>PA</given-names></name><name><surname>Gogas</surname><given-names>HJ</given-names></name><name><surname>Arance</surname><given-names>A</given-names></name><name><surname>Mandala</surname><given-names>M</given-names></name><name><surname>Liszkay</surname><given-names>G</given-names></name><name><surname>Garbe</surname><given-names>C</given-names></name><name><surname>Schadendorf</surname><given-names>D</given-names></name><name><surname>Krajsova</surname><given-names>I</given-names></name><name><surname>Gutzmer</surname><given-names>R</given-names></name><name><surname>Chiarion-Sileni</surname><given-names>V</given-names></name><name><surname>Dutriaux</surname><given-names>C</given-names></name><name><surname>de Groot</surname><given-names>JWB</given-names></name><name><surname>Yamazaki</surname><given-names>N</given-names></name><name><surname>Loquai</surname><given-names>C</given-names></name><name><surname>Moutouh-de Parseval</surname><given-names>LA</given-names></name><name><surname>Pickard</surname><given-names>MD</given-names></name><name><surname>Sandor</surname><given-names>V</given-names></name><name><surname>Robert</surname><given-names>C</given-names></name><name><surname>Flaherty</surname><given-names>KT</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial</article-title><source>The Lancet. Oncology</source><volume>19</volume><fpage>603</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(18)30142-6</pub-id><pub-id pub-id-type="pmid">29573941</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ederer</surname><given-names>M</given-names></name><name><surname>Gilles</surname><given-names>ED</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Thermodynamically feasible kinetic models of reaction networks</article-title><source>Biophysical Journal</source><volume>92</volume><fpage>1846</fpage><lpage>1857</lpage><pub-id pub-id-type="doi">10.1529/biophysj.106.094094</pub-id><pub-id pub-id-type="pmid">17208985</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisen</surname><given-names>T</given-names></name><name><surname>Ahmad</surname><given-names>T</given-names></name><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>Gore</surname><given-names>M</given-names></name><name><surname>Kaye</surname><given-names>S</given-names></name><name><surname>Marais</surname><given-names>R</given-names></name><name><surname>Gibbens</surname><given-names>I</given-names></name><name><surname>Hackett</surname><given-names>S</given-names></name><name><surname>James</surname><given-names>M</given-names></name><name><surname>Schuchter</surname><given-names>LM</given-names></name><name><surname>Nathanson</surname><given-names>KL</given-names></name><name><surname>Xia</surname><given-names>C</given-names></name><name><surname>Simantov</surname><given-names>R</given-names></name><name><surname>Schwartz</surname><given-names>B</given-names></name><name><surname>Poulin-Costello</surname><given-names>M</given-names></name><name><surname>OâDwyer</surname><given-names>PJ</given-names></name><name><surname>Ratain</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis</article-title><source>British Journal of Cancer</source><volume>95</volume><fpage>581</fpage><lpage>586</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6603291</pub-id><pub-id pub-id-type="pmid">16880785</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hagelueken</surname><given-names>G</given-names></name><name><surname>Ward</surname><given-names>R</given-names></name><name><surname>Naismith</surname><given-names>JH</given-names></name><name><surname>Schiemann</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>MtsslWizard: in silico spin-labeling and generation of distance distributions in PyMOL</article-title><source>Applied Magnetic Resonance</source><volume>42</volume><fpage>377</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.1007/s00723-012-0314-0</pub-id><pub-id pub-id-type="pmid">22448103</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haling</surname><given-names>JR</given-names></name><name><surname>Sudhamsu</surname><given-names>J</given-names></name><name><surname>Yen</surname><given-names>I</given-names></name><name><surname>Sideris</surname><given-names>S</given-names></name><name><surname>Sandoval</surname><given-names>W</given-names></name><name><surname>Phung</surname><given-names>W</given-names></name><name><surname>Bravo</surname><given-names>BJ</given-names></name><name><surname>Giannetti</surname><given-names>AM</given-names></name><name><surname>Peck</surname><given-names>A</given-names></name><name><surname>Masselot</surname><given-names>A</given-names></name><name><surname>Morales</surname><given-names>T</given-names></name><name><surname>Smith</surname><given-names>D</given-names></name><name><surname>Brandhuber</surname><given-names>BJ</given-names></name><name><surname>Hymowitz</surname><given-names>SG</given-names></name><name><surname>Malek</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling</article-title><source>Cancer Cell</source><volume>26</volume><fpage>402</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2014.07.007</pub-id><pub-id pub-id-type="pmid">25155755</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall-Jackson</surname><given-names>CA</given-names></name><name><surname>Eyers</surname><given-names>PA</given-names></name><name><surname>Cohen</surname><given-names>P</given-names></name><name><surname>Goedert</surname><given-names>M</given-names></name><name><surname>Boyle</surname><given-names>FT</given-names></name><name><surname>Hewitt</surname><given-names>N</given-names></name><name><surname>Plant</surname><given-names>H</given-names></name><name><surname>Hedge</surname><given-names>P</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Paradoxical activation of Raf by a novel Raf inhibitor</article-title><source>Chemistry &amp; Biology</source><volume>6</volume><fpage>559</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1016/s1074-5521(99)80088-x</pub-id><pub-id pub-id-type="pmid">10421767</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatzivassiliou</surname><given-names>G</given-names></name><name><surname>Song</surname><given-names>K</given-names></name><name><surname>Yen</surname><given-names>I</given-names></name><name><surname>Brandhuber</surname><given-names>BJ</given-names></name><name><surname>Anderson</surname><given-names>DJ</given-names></name><name><surname>Alvarado</surname><given-names>R</given-names></name><name><surname>Ludlam</surname><given-names>MJC</given-names></name><name><surname>Stokoe</surname><given-names>D</given-names></name><name><surname>Gloor</surname><given-names>SL</given-names></name><name><surname>Vigers</surname><given-names>G</given-names></name><name><surname>Morales</surname><given-names>T</given-names></name><name><surname>Aliagas</surname><given-names>I</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Sideris</surname><given-names>S</given-names></name><name><surname>Hoeflich</surname><given-names>KP</given-names></name><name><surname>Jaiswal</surname><given-names>BS</given-names></name><name><surname>Seshagiri</surname><given-names>S</given-names></name><name><surname>Koeppen</surname><given-names>H</given-names></name><name><surname>Belvin</surname><given-names>M</given-names></name><name><surname>Friedman</surname><given-names>LS</given-names></name><name><surname>Malek</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth</article-title><source>Nature</source><volume>464</volume><fpage>431</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1038/nature08833</pub-id><pub-id pub-id-type="pmid">20130576</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hauschild</surname><given-names>A</given-names></name><name><surname>Grob</surname><given-names>JJ</given-names></name><name><surname>Demidov</surname><given-names>LV</given-names></name><name><surname>Jouary</surname><given-names>T</given-names></name><name><surname>Gutzmer</surname><given-names>R</given-names></name><name><surname>Millward</surname><given-names>M</given-names></name><name><surname>Rutkowski</surname><given-names>P</given-names></name><name><surname>Blank</surname><given-names>CU</given-names></name><name><surname>Miller</surname><given-names>WH</given-names></name><name><surname>Kaempgen</surname><given-names>E</given-names></name><name><surname>MartÃ­n-Algarra</surname><given-names>S</given-names></name><name><surname>Karaszewska</surname><given-names>B</given-names></name><name><surname>Mauch</surname><given-names>C</given-names></name><name><surname>Chiarion-Sileni</surname><given-names>V</given-names></name><name><surname>Martin</surname><given-names>AM</given-names></name><name><surname>Swann</surname><given-names>S</given-names></name><name><surname>Haney</surname><given-names>P</given-names></name><name><surname>Mirakhur</surname><given-names>B</given-names></name><name><surname>Guckert</surname><given-names>ME</given-names></name><name><surname>Goodman</surname><given-names>V</given-names></name><name><surname>Chapman</surname><given-names>PB</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial</article-title><source>Lancet</source><volume>380</volume><fpage>358</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(12)60868-X</pub-id><pub-id pub-id-type="pmid">22735384</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heidorn</surname><given-names>SJ</given-names></name><name><surname>Milagre</surname><given-names>C</given-names></name><name><surname>Whittaker</surname><given-names>S</given-names></name><name><surname>Nourry</surname><given-names>A</given-names></name><name><surname>Niculescu-Duvas</surname><given-names>I</given-names></name><name><surname>Dhomen</surname><given-names>N</given-names></name><name><surname>Hussain</surname><given-names>J</given-names></name><name><surname>Reis-Filho</surname><given-names>JS</given-names></name><name><surname>Springer</surname><given-names>CJ</given-names></name><name><surname>Pritchard</surname><given-names>C</given-names></name><name><surname>Marais</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF</article-title><source>Cell</source><volume>140</volume><fpage>209</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.12.040</pub-id><pub-id pub-id-type="pmid">20141835</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Stites</surname><given-names>EC</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Germino</surname><given-names>EA</given-names></name><name><surname>Meharena</surname><given-names>HS</given-names></name><name><surname>Stork</surname><given-names>PJS</given-names></name><name><surname>Kornev</surname><given-names>AP</given-names></name><name><surname>Taylor</surname><given-names>SS</given-names></name><name><surname>Shaw</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Allosteric activation of functionally asymmetric RAF kinase dimers</article-title><source>Cell</source><volume>154</volume><fpage>1036</fpage><lpage>1046</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.07.046</pub-id><pub-id pub-id-type="pmid">23993095</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>T</given-names></name><name><surname>Lavoie</surname><given-names>H</given-names></name><name><surname>Sahmi</surname><given-names>M</given-names></name><name><surname>David</surname><given-names>M</given-names></name><name><surname>Hilt</surname><given-names>C</given-names></name><name><surname>Hammell</surname><given-names>A</given-names></name><name><surname>Therrien</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>1211</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-017-01274-0</pub-id><pub-id pub-id-type="pmid">29084939</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>KA</given-names></name><name><surname>Simpson</surname><given-names>ZB</given-names></name><name><surname>Blom</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>FitSpace explorer: an algorithm to evaluate multidimensional parameter space in fitting kinetic data</article-title><source>Analytical Biochemistry</source><volume>387</volume><fpage>30</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.ab.2008.12.025</pub-id><pub-id pub-id-type="pmid">19168024</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joseph</surname><given-names>EW</given-names></name><name><surname>Pratilas</surname><given-names>CA</given-names></name><name><surname>Poulikakos</surname><given-names>PI</given-names></name><name><surname>Tadi</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Taylor</surname><given-names>BS</given-names></name><name><surname>Halilovic</surname><given-names>E</given-names></name><name><surname>Persaud</surname><given-names>Y</given-names></name><name><surname>Xing</surname><given-names>F</given-names></name><name><surname>Viale</surname><given-names>A</given-names></name><name><surname>Tsai</surname><given-names>J</given-names></name><name><surname>Chapman</surname><given-names>PB</given-names></name><name><surname>Bollag</surname><given-names>G</given-names></name><name><surname>Solit</surname><given-names>DB</given-names></name><name><surname>Rosen</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner</article-title><source>PNAS</source><volume>107</volume><fpage>14903</fpage><lpage>14908</lpage><pub-id pub-id-type="doi">10.1073/pnas.1008990107</pub-id><pub-id pub-id-type="pmid">20668238</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karoulia</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Ahmed</surname><given-names>TA</given-names></name><name><surname>Xin</surname><given-names>Q</given-names></name><name><surname>Bollard</surname><given-names>J</given-names></name><name><surname>Krepler</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Bollag</surname><given-names>G</given-names></name><name><surname>Herlyn</surname><given-names>M</given-names></name><name><surname>Fagin</surname><given-names>JA</given-names></name><name><surname>Lujambio</surname><given-names>A</given-names></name><name><surname>Gavathiotis</surname><given-names>E</given-names></name><name><surname>Poulikakos</surname><given-names>PI</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>An integrated model of RAF inhibitor action predicts inhibitor activity against oncogenic BRAF signaling</article-title><source>Cancer Cell</source><volume>30</volume><fpage>485</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2016.06.024</pub-id><pub-id pub-id-type="pmid">27523909</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kholodenko</surname><given-names>BN</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Drug resistance resulting from kinase dimerization is rationalized by thermodynamic factors describing allosteric inhibitor effects</article-title><source>Cell Reports</source><volume>12</volume><fpage>1939</fpage><lpage>1949</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.08.014</pub-id><pub-id pub-id-type="pmid">26344764</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kondo</surname><given-names>Y</given-names></name><name><surname>OgnjenoviÄ</surname><given-names>J</given-names></name><name><surname>Banerjee</surname><given-names>S</given-names></name><name><surname>Karandur</surname><given-names>D</given-names></name><name><surname>Merk</surname><given-names>A</given-names></name><name><surname>Kulhanek</surname><given-names>K</given-names></name><name><surname>Wong</surname><given-names>K</given-names></name><name><surname>Roose</surname><given-names>JP</given-names></name><name><surname>Subramaniam</surname><given-names>S</given-names></name><name><surname>Kuriyan</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cryo-EM structure of a dimeric B-Raf:14-3-3 complex reveals asymmetry in the active sites of B-Raf kinases</article-title><source>Science</source><volume>366</volume><fpage>109</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1126/science.aay0543</pub-id><pub-id pub-id-type="pmid">31604311</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>LP</given-names></name><name><surname>Fer</surname><given-names>N</given-names></name><name><surname>Burgan</surname><given-names>W</given-names></name><name><surname>Wall</surname><given-names>VE</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Soppet</surname><given-names>D</given-names></name><name><surname>Esposito</surname><given-names>D</given-names></name><name><surname>Nissley</surname><given-names>DV</given-names></name><name><surname>McCormick</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Classical RAS proteins are not essential for paradoxical ERK activation induced by RAF inhibitors</article-title><source>PNAS</source><volume>119</volume><elocation-id>e2113491119</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2113491119</pub-id><pub-id pub-id-type="pmid">35091470</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavoie</surname><given-names>H</given-names></name><name><surname>Thevakumaran</surname><given-names>N</given-names></name><name><surname>Gavory</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>JJ</given-names></name><name><surname>Padeganeh</surname><given-names>A</given-names></name><name><surname>Guiral</surname><given-names>S</given-names></name><name><surname>Duchaine</surname><given-names>J</given-names></name><name><surname>Mao</surname><given-names>DYL</given-names></name><name><surname>Bouvier</surname><given-names>M</given-names></name><name><surname>Sicheri</surname><given-names>F</given-names></name><name><surname>Therrien</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization</article-title><source>Nature Chemical Biology</source><volume>9</volume><fpage>428</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1257</pub-id><pub-id pub-id-type="pmid">23685672</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavoie</surname><given-names>H</given-names></name><name><surname>Therrien</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Regulation of RAF protein kinases in ERK signalling</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>16</volume><fpage>281</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1038/nrm3979</pub-id><pub-id pub-id-type="pmid">25907612</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavoie</surname><given-names>H</given-names></name><name><surname>Sahmi</surname><given-names>M</given-names></name><name><surname>Maisonneuve</surname><given-names>P</given-names></name><name><surname>Marullo</surname><given-names>SA</given-names></name><name><surname>Thevakumaran</surname><given-names>N</given-names></name><name><surname>Jin</surname><given-names>T</given-names></name><name><surname>Kurinov</surname><given-names>I</given-names></name><name><surname>Sicheri</surname><given-names>F</given-names></name><name><surname>Therrien</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>MEK drives BRAF activation through allosteric control of KSR proteins</article-title><source>Nature</source><volume>554</volume><fpage>549</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1038/nature25478</pub-id><pub-id pub-id-type="pmid">29433126</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liau</surname><given-names>NPD</given-names></name><name><surname>Venkatanarayan</surname><given-names>A</given-names></name><name><surname>Quinn</surname><given-names>JG</given-names></name><name><surname>Phung</surname><given-names>W</given-names></name><name><surname>Malek</surname><given-names>S</given-names></name><name><surname>Hymowitz</surname><given-names>SG</given-names></name><name><surname>Sudhamsu</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Dimerization induced by C-Terminal 14-3-3 binding is sufficient for BRAF kinase activation</article-title><source>Biochemistry</source><volume>59</volume><fpage>3982</fpage><lpage>3992</lpage><pub-id pub-id-type="doi">10.1021/acs.biochem.0c00517</pub-id><pub-id pub-id-type="pmid">32970425</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Majumdar</surname><given-names>A</given-names></name><name><surname>Burban</surname><given-names>DJ</given-names></name><name><surname>Muretta</surname><given-names>JM</given-names></name><name><surname>Thompson</surname><given-names>AR</given-names></name><name><surname>Engel</surname><given-names>TA</given-names></name><name><surname>Rasmussen</surname><given-names>DM</given-names></name><name><surname>Subrahmanian</surname><given-names>MV</given-names></name><name><surname>Veglia</surname><given-names>G</given-names></name><name><surname>Thomas</surname><given-names>DD</given-names></name><name><surname>Levinson</surname><given-names>NM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Allostery governs Cdk2 activation and differential recognition of CDK inhibitors</article-title><source>Nature Chemical Biology</source><volume>17</volume><fpage>456</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1038/s41589-020-00725-y</pub-id><pub-id pub-id-type="pmid">33526892</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez Fiesco</surname><given-names>JA</given-names></name><name><surname>Durrant</surname><given-names>DE</given-names></name><name><surname>Morrison</surname><given-names>DK</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Structural insights into the BRAF monomer-to-dimer transition mediated by RAS binding</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>486</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-28084-3</pub-id><pub-id pub-id-type="pmid">35078985</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>A</given-names></name><name><surname>Arita</surname><given-names>T</given-names></name><name><surname>Tsuchiya</surname><given-names>S</given-names></name><name><surname>Donelan</surname><given-names>J</given-names></name><name><surname>Chouitar</surname><given-names>J</given-names></name><name><surname>Carideo</surname><given-names>E</given-names></name><name><surname>Galvin</surname><given-names>K</given-names></name><name><surname>Okaniwa</surname><given-names>M</given-names></name><name><surname>Ishikawa</surname><given-names>T</given-names></name><name><surname>Yoshida</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma</article-title><source>Cancer Research</source><volume>73</volume><fpage>7043</fpage><lpage>7055</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-1825</pub-id><pub-id pub-id-type="pmid">24121489</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nazarian</surname><given-names>R</given-names></name><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Kong</surname><given-names>X</given-names></name><name><surname>Koya</surname><given-names>RC</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Lee</surname><given-names>MK</given-names></name><name><surname>Attar</surname><given-names>N</given-names></name><name><surname>Sazegar</surname><given-names>H</given-names></name><name><surname>Chodon</surname><given-names>T</given-names></name><name><surname>Nelson</surname><given-names>SF</given-names></name><name><surname>McArthur</surname><given-names>G</given-names></name><name><surname>Sosman</surname><given-names>JA</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>Lo</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation</article-title><source>Nature</source><volume>468</volume><fpage>973</fpage><lpage>977</lpage><pub-id pub-id-type="doi">10.1038/nature09626</pub-id><pub-id pub-id-type="pmid">21107323</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okaniwa</surname><given-names>M</given-names></name><name><surname>Hirose</surname><given-names>M</given-names></name><name><surname>Arita</surname><given-names>T</given-names></name><name><surname>Yabuki</surname><given-names>M</given-names></name><name><surname>Nakamura</surname><given-names>A</given-names></name><name><surname>Takagi</surname><given-names>T</given-names></name><name><surname>Kawamoto</surname><given-names>T</given-names></name><name><surname>Uchiyama</surname><given-names>N</given-names></name><name><surname>Sumita</surname><given-names>A</given-names></name><name><surname>Tsutsumi</surname><given-names>S</given-names></name><name><surname>Tottori</surname><given-names>T</given-names></name><name><surname>Inui</surname><given-names>Y</given-names></name><name><surname>Sang</surname><given-names>BC</given-names></name><name><surname>Yano</surname><given-names>J</given-names></name><name><surname>Aertgeerts</surname><given-names>K</given-names></name><name><surname>Yoshida</surname><given-names>S</given-names></name><name><surname>Ishikawa</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives</article-title><source>Journal of Medicinal Chemistry</source><volume>56</volume><fpage>6478</fpage><lpage>6494</lpage><pub-id pub-id-type="doi">10.1021/jm400778d</pub-id><pub-id pub-id-type="pmid">23906342</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owsley</surname><given-names>J</given-names></name><name><surname>Stein</surname><given-names>MK</given-names></name><name><surname>Porter</surname><given-names>J</given-names></name><name><surname>In</surname><given-names>GK</given-names></name><name><surname>Salem</surname><given-names>M</given-names></name><name><surname>OâDay</surname><given-names>S</given-names></name><name><surname>Elliott</surname><given-names>A</given-names></name><name><surname>Poorman</surname><given-names>K</given-names></name><name><surname>Gibney</surname><given-names>G</given-names></name><name><surname>VanderWalde</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database</article-title><source>Experimental Biology and Medicine</source><volume>246</volume><fpage>31</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1177/1535370220959657</pub-id><pub-id pub-id-type="pmid">33019809</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>E</given-names></name><name><surname>Rawson</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>BW</given-names></name><name><surname>Ficarro</surname><given-names>SB</given-names></name><name><surname>Pino</surname><given-names>GGD</given-names></name><name><surname>Sharif</surname><given-names>H</given-names></name><name><surname>Marto</surname><given-names>JA</given-names></name><name><surname>Jeon</surname><given-names>H</given-names></name><name><surname>Eck</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Architecture of autoinhibited and active BRAF-MEK1-14-3-3 complexes</article-title><source>Nature</source><volume>575</volume><fpage>545</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1660-y</pub-id><pub-id pub-id-type="pmid">31581174</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>SB</given-names></name><name><surname>Henry</surname><given-names>JR</given-names></name><name><surname>Kaufman</surname><given-names>MD</given-names></name><name><surname>Lu</surname><given-names>WP</given-names></name><name><surname>Smith</surname><given-names>BD</given-names></name><name><surname>Vogeti</surname><given-names>S</given-names></name><name><surname>Rutkoski</surname><given-names>TJ</given-names></name><name><surname>Wise</surname><given-names>S</given-names></name><name><surname>Chun</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Van Horn</surname><given-names>RD</given-names></name><name><surname>Yin</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Yadav</surname><given-names>V</given-names></name><name><surname>Chen</surname><given-names>SH</given-names></name><name><surname>Gong</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Webster</surname><given-names>Y</given-names></name><name><surname>Buchanan</surname><given-names>S</given-names></name><name><surname>Mochalkin</surname><given-names>I</given-names></name><name><surname>Huber</surname><given-names>L</given-names></name><name><surname>Kays</surname><given-names>L</given-names></name><name><surname>Donoho</surname><given-names>GP</given-names></name><name><surname>Walgren</surname><given-names>J</given-names></name><name><surname>McCann</surname><given-names>D</given-names></name><name><surname>Patel</surname><given-names>P</given-names></name><name><surname>Conti</surname><given-names>I</given-names></name><name><surname>Plowman</surname><given-names>GD</given-names></name><name><surname>Starling</surname><given-names>JJ</given-names></name><name><surname>Flynn</surname><given-names>DL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Inhibition of RAF isoforms and active dimers by LY3009120 leads to anti-tumor activities in RAS or BRAF mutant cancers</article-title><source>Cancer Cell</source><volume>28</volume><fpage>384</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2015.08.002</pub-id><pub-id pub-id-type="pmid">26343583</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poulikakos</surname><given-names>PI</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Bollag</surname><given-names>G</given-names></name><name><surname>Shokat</surname><given-names>KM</given-names></name><name><surname>Rosen</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF</article-title><source>Nature</source><volume>464</volume><fpage>427</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1038/nature08902</pub-id><pub-id pub-id-type="pmid">20179705</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poulikakos</surname><given-names>PI</given-names></name><name><surname>Persaud</surname><given-names>Y</given-names></name><name><surname>Janakiraman</surname><given-names>M</given-names></name><name><surname>Kong</surname><given-names>X</given-names></name><name><surname>Ng</surname><given-names>C</given-names></name><name><surname>Moriceau</surname><given-names>G</given-names></name><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Atefi</surname><given-names>M</given-names></name><name><surname>Titz</surname><given-names>B</given-names></name><name><surname>Gabay</surname><given-names>MT</given-names></name><name><surname>Salton</surname><given-names>M</given-names></name><name><surname>Dahlman</surname><given-names>KB</given-names></name><name><surname>Tadi</surname><given-names>M</given-names></name><name><surname>Wargo</surname><given-names>JA</given-names></name><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>Kelley</surname><given-names>MC</given-names></name><name><surname>Misteli</surname><given-names>T</given-names></name><name><surname>Chapman</surname><given-names>PB</given-names></name><name><surname>Sosman</surname><given-names>JA</given-names></name><name><surname>Graeber</surname><given-names>TG</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>Lo</surname><given-names>RS</given-names></name><name><surname>Rosen</surname><given-names>N</given-names></name><name><surname>Solit</surname><given-names>DB</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)</article-title><source>Nature</source><volume>480</volume><fpage>387</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1038/nature10662</pub-id><pub-id pub-id-type="pmid">22113612</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Proietti</surname><given-names>I</given-names></name><name><surname>Skroza</surname><given-names>N</given-names></name><name><surname>Bernardini</surname><given-names>N</given-names></name><name><surname>Tolino</surname><given-names>E</given-names></name><name><surname>Balduzzi</surname><given-names>V</given-names></name><name><surname>Marchesiello</surname><given-names>A</given-names></name><name><surname>Michelini</surname><given-names>S</given-names></name><name><surname>Volpe</surname><given-names>S</given-names></name><name><surname>Mambrin</surname><given-names>A</given-names></name><name><surname>Mangino</surname><given-names>G</given-names></name><name><surname>Romeo</surname><given-names>G</given-names></name><name><surname>Maddalena</surname><given-names>P</given-names></name><name><surname>Rees</surname><given-names>C</given-names></name><name><surname>Potenza</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mechanisms of acquired BRAF inhibitor resistance in melanoma: a systematic review</article-title><source>Cancers</source><volume>12</volume><elocation-id>2801</elocation-id><pub-id pub-id-type="doi">10.3390/cancers12102801</pub-id><pub-id pub-id-type="pmid">33003483</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajakulendran</surname><given-names>T</given-names></name><name><surname>Sahmi</surname><given-names>M</given-names></name><name><surname>LefranÃ§ois</surname><given-names>M</given-names></name><name><surname>Sicheri</surname><given-names>F</given-names></name><name><surname>Therrien</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>A dimerization-dependent mechanism drives RAF catalytic activation</article-title><source>Nature</source><volume>461</volume><fpage>542</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1038/nature08314</pub-id><pub-id pub-id-type="pmid">19727074</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>RÃ¶ring</surname><given-names>M</given-names></name><name><surname>Herr</surname><given-names>R</given-names></name><name><surname>Fiala</surname><given-names>GJ</given-names></name><name><surname>Heilmann</surname><given-names>K</given-names></name><name><surname>Braun</surname><given-names>S</given-names></name><name><surname>Eisenhardt</surname><given-names>AE</given-names></name><name><surname>Halbach</surname><given-names>S</given-names></name><name><surname>Capper</surname><given-names>D</given-names></name><name><surname>von Deimling</surname><given-names>A</given-names></name><name><surname>Schamel</surname><given-names>WW</given-names></name><name><surname>Saunders</surname><given-names>DN</given-names></name><name><surname>Brummer</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling</article-title><source>The EMBO Journal</source><volume>31</volume><fpage>2629</fpage><lpage>2647</lpage><pub-id pub-id-type="doi">10.1038/emboj.2012.100</pub-id><pub-id pub-id-type="pmid">22510884</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rushworth</surname><given-names>LK</given-names></name><name><surname>Hindley</surname><given-names>AD</given-names></name><name><surname>OâNeill</surname><given-names>E</given-names></name><name><surname>Kolch</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Regulation and role of Raf-1/B-Raf heterodimerization</article-title><source>Molecular and Cellular Biology</source><volume>26</volume><fpage>2262</fpage><lpage>2272</lpage><pub-id pub-id-type="doi">10.1128/MCB.26.6.2262-2272.2006</pub-id><pub-id pub-id-type="pmid">16508002</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schaaf</surname><given-names>TM</given-names></name><name><surname>Peterson</surname><given-names>KC</given-names></name><name><surname>Grant</surname><given-names>BD</given-names></name><name><surname>Thomas</surname><given-names>DD</given-names></name><name><surname>Gillispie</surname><given-names>GD</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Spectral unmixing plate reader: high-throughput, high-precision FRET assays in living cells</article-title><source>SLAS Discovery</source><volume>22</volume><fpage>250</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1177/1087057116679637</pub-id><pub-id pub-id-type="pmid">27879398</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>F</given-names></name><name><surname>Viros</surname><given-names>A</given-names></name><name><surname>Milagre</surname><given-names>C</given-names></name><name><surname>Trunzer</surname><given-names>K</given-names></name><name><surname>Bollag</surname><given-names>G</given-names></name><name><surname>Spleiss</surname><given-names>O</given-names></name><name><surname>Reis-Filho</surname><given-names>JS</given-names></name><name><surname>Kong</surname><given-names>X</given-names></name><name><surname>Koya</surname><given-names>RC</given-names></name><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>Chapman</surname><given-names>PB</given-names></name><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Hayward</surname><given-names>R</given-names></name><name><surname>Martin</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Hilton</surname><given-names>H</given-names></name><name><surname>Hang</surname><given-names>JS</given-names></name><name><surname>Noe</surname><given-names>J</given-names></name><name><surname>Lambros</surname><given-names>M</given-names></name><name><surname>Geyer</surname><given-names>F</given-names></name><name><surname>Dhomen</surname><given-names>N</given-names></name><name><surname>Niculescu-Duvaz</surname><given-names>I</given-names></name><name><surname>Zambon</surname><given-names>A</given-names></name><name><surname>Niculescu-Duvaz</surname><given-names>D</given-names></name><name><surname>Preece</surname><given-names>N</given-names></name><name><surname>Robert</surname><given-names>L</given-names></name><name><surname>Otte</surname><given-names>NJ</given-names></name><name><surname>Mok</surname><given-names>S</given-names></name><name><surname>Kee</surname><given-names>D</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Habets</surname><given-names>G</given-names></name><name><surname>Burton</surname><given-names>EA</given-names></name><name><surname>Wong</surname><given-names>B</given-names></name><name><surname>Nguyen</surname><given-names>H</given-names></name><name><surname>Kockx</surname><given-names>M</given-names></name><name><surname>Andries</surname><given-names>L</given-names></name><name><surname>Lestini</surname><given-names>B</given-names></name><name><surname>Nolop</surname><given-names>KB</given-names></name><name><surname>Lee</surname><given-names>RJ</given-names></name><name><surname>Joe</surname><given-names>AK</given-names></name><name><surname>Troy</surname><given-names>JL</given-names></name><name><surname>Gonzalez</surname><given-names>R</given-names></name><name><surname>Hutson</surname><given-names>TE</given-names></name><name><surname>Puzanov</surname><given-names>I</given-names></name><name><surname>Chmielowski</surname><given-names>B</given-names></name><name><surname>Springer</surname><given-names>CJ</given-names></name><name><surname>McArthur</surname><given-names>GA</given-names></name><name><surname>Sosman</surname><given-names>JA</given-names></name><name><surname>Lo</surname><given-names>RS</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>Marais</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors</article-title><source>The New England Journal of Medicine</source><volume>366</volume><fpage>207</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1105358</pub-id><pub-id pub-id-type="pmid">22256804</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>RJ</given-names></name><name><surname>Hollebecque</surname><given-names>A</given-names></name><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>Shapiro</surname><given-names>GI</given-names></name><name><surname>Rodon Ahnert</surname><given-names>J</given-names></name><name><surname>Millward</surname><given-names>MJ</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Gao</surname><given-names>L</given-names></name><name><surname>Sykes</surname><given-names>A</given-names></name><name><surname>Willard</surname><given-names>MD</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name><name><surname>Schade</surname><given-names>AE</given-names></name><name><surname>Crowe</surname><given-names>K</given-names></name><name><surname>Flynn</surname><given-names>DL</given-names></name><name><surname>Kaufman</surname><given-names>MD</given-names></name><name><surname>Henry</surname><given-names>JR</given-names></name><name><surname>Peng</surname><given-names>SB</given-names></name><name><surname>Benhadji</surname><given-names>KA</given-names></name><name><surname>Conti</surname><given-names>I</given-names></name><name><surname>Gordon</surname><given-names>MS</given-names></name><name><surname>Tiu</surname><given-names>RV</given-names></name><name><surname>Hong</surname><given-names>DS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A phase i study of LY3009120, A Pan-RAF inhibitor, in patients with advanced or metastatic cancer</article-title><source>Molecular Cancer Therapeutics</source><volume>19</volume><fpage>460</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-19-0681</pub-id><pub-id pub-id-type="pmid">31645440</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thevakumaran</surname><given-names>N</given-names></name><name><surname>Lavoie</surname><given-names>H</given-names></name><name><surname>Critton</surname><given-names>DA</given-names></name><name><surname>Tebben</surname><given-names>A</given-names></name><name><surname>Marinier</surname><given-names>A</given-names></name><name><surname>Sicheri</surname><given-names>F</given-names></name><name><surname>Therrien</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>22</volume><fpage>37</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1038/nsmb.2924</pub-id><pub-id pub-id-type="pmid">25437913</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Venison</data-title><version designator="swh:1:rev:652831dae45127fe2ff7cdf0188d9703d9e768f8">swh:1:rev:652831dae45127fe2ff7cdf0188d9703d9e768f8</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:1d1c3270a76015e6f0a2b96ef99a7c134027e4e7;origin=https://github.com/thompsar/Venison;visit=swh:1:snp:71e7db0713a1908384d6d87dbe47c158ef2e85eb;anchor=swh:1:rev:652831dae45127fe2ff7cdf0188d9703d9e768f8">https://archive.softwareheritage.org/swh:1:dir:1d1c3270a76015e6f0a2b96ef99a7c134027e4e7;origin=https://github.com/thompsar/Venison;visit=swh:1:snp:71e7db0713a1908384d6d87dbe47c158ef2e85eb;anchor=swh:1:rev:652831dae45127fe2ff7cdf0188d9703d9e768f8</ext-link></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tkacik</surname><given-names>E</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Gonzalez-Del Pino</surname><given-names>G</given-names></name><name><surname>Ha</surname><given-names>BH</given-names></name><name><surname>Vinals</surname><given-names>J</given-names></name><name><surname>Park</surname><given-names>E</given-names></name><name><surname>Beyett</surname><given-names>TS</given-names></name><name><surname>Eck</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib</article-title><source>The Journal of Biological Chemistry</source><volume>299</volume><elocation-id>104634</elocation-id><pub-id pub-id-type="doi">10.1016/j.jbc.2023.104634</pub-id><pub-id pub-id-type="pmid">36963492</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>JT</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Cho</surname><given-names>H</given-names></name><name><surname>Mamo</surname><given-names>S</given-names></name><name><surname>Bremer</surname><given-names>R</given-names></name><name><surname>Gillette</surname><given-names>S</given-names></name><name><surname>Kong</surname><given-names>J</given-names></name><name><surname>Haass</surname><given-names>NK</given-names></name><name><surname>Sproesser</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Smalley</surname><given-names>KSM</given-names></name><name><surname>Fong</surname><given-names>D</given-names></name><name><surname>Zhu</surname><given-names>YL</given-names></name><name><surname>Marimuthu</surname><given-names>A</given-names></name><name><surname>Nguyen</surname><given-names>H</given-names></name><name><surname>Lam</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Cheung</surname><given-names>I</given-names></name><name><surname>Rice</surname><given-names>J</given-names></name><name><surname>Suzuki</surname><given-names>Y</given-names></name><name><surname>Luu</surname><given-names>C</given-names></name><name><surname>Settachatgul</surname><given-names>C</given-names></name><name><surname>Shellooe</surname><given-names>R</given-names></name><name><surname>Cantwell</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Schlessinger</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>KYJ</given-names></name><name><surname>West</surname><given-names>BL</given-names></name><name><surname>Powell</surname><given-names>B</given-names></name><name><surname>Habets</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Ibrahim</surname><given-names>PN</given-names></name><name><surname>Hirth</surname><given-names>P</given-names></name><name><surname>Artis</surname><given-names>DR</given-names></name><name><surname>Herlyn</surname><given-names>M</given-names></name><name><surname>Bollag</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity</article-title><source>PNAS</source><volume>105</volume><fpage>3041</fpage><lpage>3046</lpage><pub-id pub-id-type="doi">10.1073/pnas.0711741105</pub-id><pub-id pub-id-type="pmid">18287029</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagle</surname><given-names>N</given-names></name><name><surname>Emery</surname><given-names>C</given-names></name><name><surname>Berger</surname><given-names>MF</given-names></name><name><surname>Davis</surname><given-names>MJ</given-names></name><name><surname>Sawyer</surname><given-names>A</given-names></name><name><surname>Pochanard</surname><given-names>P</given-names></name><name><surname>Kehoe</surname><given-names>SM</given-names></name><name><surname>Johannessen</surname><given-names>CM</given-names></name><name><surname>Macconaill</surname><given-names>LE</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name><name><surname>Meyerson</surname><given-names>M</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling</article-title><source>Journal of Clinical Oncology</source><volume>29</volume><fpage>3085</fpage><lpage>3096</lpage><pub-id pub-id-type="doi">10.1200/JCO.2010.33.2312</pub-id><pub-id pub-id-type="pmid">21383288</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>PTC</given-names></name><name><surname>Garnett</surname><given-names>MJ</given-names></name><name><surname>Roe</surname><given-names>SM</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Niculescu-Duvaz</surname><given-names>D</given-names></name><name><surname>Good</surname><given-names>VM</given-names></name><name><surname>Jones</surname><given-names>CM</given-names></name><name><surname>Marshall</surname><given-names>CJ</given-names></name><name><surname>Springer</surname><given-names>CJ</given-names></name><name><surname>Barford</surname><given-names>D</given-names></name><name><surname>Marais</surname><given-names>R</given-names></name><collab>Cancer Genome Project</collab></person-group><year iso-8601-date="2004">2004</year><article-title>Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF</article-title><source>Cell</source><volume>116</volume><fpage>855</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(04)00215-6</pub-id><pub-id pub-id-type="pmid">15035987</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>CK</given-names></name><name><surname>Slupsky</surname><given-names>JR</given-names></name><name><surname>Kalmes</surname><given-names>HA</given-names></name><name><surname>Rapp</surname><given-names>UR</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Active ras induces heterodimerization of cRaf and BRaf</article-title><source>Cancer Research</source><volume>61</volume><fpage>3595</fpage><lpage>3598</lpage><pub-id pub-id-type="pmid">11325826</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wellbrock</surname><given-names>C</given-names></name><name><surname>Karasarides</surname><given-names>M</given-names></name><name><surname>Marais</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The RAF proteins take centre stage</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>5</volume><fpage>875</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.1038/nrm1498</pub-id><pub-id pub-id-type="pmid">15520807</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>Z</given-names></name><name><surname>Torres</surname><given-names>NM</given-names></name><name><surname>Tao</surname><given-names>A</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Luo</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>de Stanchina</surname><given-names>E</given-names></name><name><surname>Abdel-Wahab</surname><given-names>O</given-names></name><name><surname>Solit</surname><given-names>DB</given-names></name><name><surname>Poulikakos</surname><given-names>PI</given-names></name><name><surname>Rosen</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>BRAF Mutants Evade ERK-dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibition</article-title><source>Cancer Cell</source><volume>28</volume><fpage>370</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2015.08.001</pub-id><pub-id pub-id-type="pmid">26343582</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>YE</given-names></name><name><surname>Woodward</surname><given-names>CN</given-names></name><name><surname>Narasimhan</surname><given-names>NI</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Absorption, metabolism, and excretion of [<sup>14</sup>C]ponatinib after a single oral dose in humans</article-title><source>Cancer Chemotherapy and Pharmacology</source><volume>79</volume><fpage>507</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1007/s00280-017-3240-x</pub-id><pub-id pub-id-type="pmid">28184964</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yen</surname><given-names>I</given-names></name><name><surname>Shanahan</surname><given-names>F</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Hong</surname><given-names>YS</given-names></name><name><surname>Shin</surname><given-names>SJ</given-names></name><name><surname>Moore</surname><given-names>AR</given-names></name><name><surname>Sudhamsu</surname><given-names>J</given-names></name><name><surname>Chang</surname><given-names>MT</given-names></name><name><surname>Bae</surname><given-names>I</given-names></name><name><surname>Dela Cruz</surname><given-names>D</given-names></name><name><surname>Hunsaker</surname><given-names>T</given-names></name><name><surname>Klijn</surname><given-names>C</given-names></name><name><surname>Liau</surname><given-names>NPD</given-names></name><name><surname>Lin</surname><given-names>E</given-names></name><name><surname>Martin</surname><given-names>SE</given-names></name><name><surname>Modrusan</surname><given-names>Z</given-names></name><name><surname>Piskol</surname><given-names>R</given-names></name><name><surname>Segal</surname><given-names>E</given-names></name><name><surname>Venkatanarayan</surname><given-names>A</given-names></name><name><surname>Ye</surname><given-names>X</given-names></name><name><surname>Yin</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Kim</surname><given-names>JS</given-names></name><name><surname>Lim</surname><given-names>HS</given-names></name><name><surname>Kim</surname><given-names>KP</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Han</surname><given-names>HS</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Kim</surname><given-names>ST</given-names></name><name><surname>Jung</surname><given-names>M</given-names></name><name><surname>Hong</surname><given-names>YH</given-names></name><name><surname>Noh</surname><given-names>YS</given-names></name><name><surname>Choi</surname><given-names>M</given-names></name><name><surname>Han</surname><given-names>O</given-names></name><name><surname>Nowicka</surname><given-names>M</given-names></name><name><surname>Srinivasan</surname><given-names>S</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>TW</given-names></name><name><surname>Malek</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma</article-title><source>Nature</source><volume>594</volume><fpage>418</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03515-1</pub-id><pub-id pub-id-type="pmid">33953400</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.95481.2.sa0</article-id><title-group><article-title>eLife assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Andreotti</surname><given-names>Amy H</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Iowa State University</institution><country>United States</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Compelling</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>This elegant study presents <bold>important</bold> findings into how small molecules that were originally developed to inhibit the oncogenic kinase, BRAF, instead trigger activation of this kinase target. <bold>Compelling</bold> and comprehensive evidence supports a new allosteric model to explain the paradoxical activation. This rigorous work will be of great interest to biochemists, structural biologists, and those working on strategies to inhibit kinases in the context of human disease.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.95481.2.sa1</article-id><title-group><article-title>Reviewer #1 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>The authors quantitatively describe the complex binding equilibria of BRAF and its inhibitors resulting in some cases in the paradoxical activation of BRAF dimer when bound to ATP competitive inhibitors. The authors use a biophysical tour de force involving FRET binding assays, NMR, kinase activity assays, and DEER spectroscopy.</p><p>Strengths:</p><p>The strengths of the study are the beautifully conducted assays that allow for a thorough characterization of the allostery in this complex system. Additionally, the use of F-NMR and DEER spectroscopy provides important insights into the details of the process.</p><p>The resulting model for binding of inhibitors and dimerization (Figure 4) is very helpful.</p><p>Weaknesses:</p><p>This is a complex system and its communication is inherently challenging. It might be of interest to the broader readership to understand the implications of the model for drug development and therapy.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.95481.2.sa2</article-id><title-group><article-title>Reviewer #2 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>This manuscript uses FRET, 19F-NMR, and DEER/EPR solution measurements to examine the allosteric effects of a panel of BRAF inhibitors (BRAFi). These include first-generation aC-out BRAFi, and more recent Type I and Type II aC-in inhibitors. Intermolecular FRET measurements quantify Kd for BRAF dimerization and inhibitor binding to the first and second subunits. Distinct patterns are found between aC-in BRAFi, where Type I BRAFi binds equally well to the first and second subunits within dimeric BRAF. In contrast, Type II BRAFi shows stronger affinity for the first subunit and weaker affinity for the second subunit, an effect named &quot;allosteric asymmetry&quot;. Allosteric asymmetry has the potential for Type II inhibitors to promote dimerization while favoring occupancy of only one subunit (BBD form), leading to the enrichment of an active dimer.</p><p>Measurements of in vitro BRAF kinase activity correlate amazingly well with the calculated amounts of the half-site-inhibited BBD forms with Type II inhibitors. This suggests that the allosteric asymmetry mechanism explains paradoxical activation by this class of inhibitors. DEER/EPR measurements further examine the positioning of helix aC. They show systematic outward movement of aC with Type II inhibitors, relative to the aC-in state with Type I inhibitors, and further show that helix aC adopts multiple states and is therefore dynamic in apo BRAF. This makes a strong case that negative cooperativity between sites in the BRAF dimer can account for paradoxical kinase activation by Type II inhibitors by creating a half-site-occupied homodimer, BBD. In contrast, Type I inhibitors and aC-out inhibitors do not fit this model, and are therefore proposed to be explained by previously proposed models involving negative allostery between subunits in BRAF-CRAF heterodimers, RAS priming, and transactivation.</p><p>Strengths:</p><p>This study integrates orthogonal spectroscopic and kinetic strategies to characterize BRAF dynamics and determine how it impacts inhibitor allostery. The unique combination of approaches presented in this study represents a road map for future work in the important area of protein kinase dynamics. The work represents a worthy contribution not only to the field of BRAF regulation but to protein kinases in general.</p><p>Weaknesses:</p><p>Some questions remain regarding the proposed model for Type II inhibitors and its comparison to Type I and aC-out inhibitors that would be useful to clarify. Specifically, it would be helpful to address whether the activation of BRAF by Type II inhibitors, while strongly correlated with BBD model predictions in vitro, also depends on CRAF via BRAF-CRAF in cells and therefore overlaps with the mechanisms of paradoxical activation by Type I and aC-out inhibitors.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.95481.2.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rasmussen</surname><given-names>Damien M</given-names></name><role specific-use="author">Author</role><aff><institution>University of Minnesota</institution><addr-line><named-content content-type="city">Minneapolis</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Semonis</surname><given-names>Manny M</given-names></name><role specific-use="author">Author</role><aff><institution>University of Minnesota</institution><addr-line><named-content content-type="city">Minneapolis</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Greene</surname><given-names>Joseph T</given-names></name><role specific-use="author">Author</role><aff><institution>University of Minnesota</institution><addr-line><named-content content-type="city">Minneapolis</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Muretta</surname><given-names>Joseph M</given-names></name><role specific-use="author">Author</role><aff><institution>University of Minnesota</institution><addr-line><named-content content-type="city">Minneapolis</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Thompson</surname><given-names>Andrew R</given-names></name><role specific-use="author">Author</role><aff><institution>University of Minnesota</institution><addr-line><named-content content-type="city">Minneapolis</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Toledo Ramos</surname><given-names>Silvia</given-names></name><role specific-use="author">Author</role><aff><institution>University of Minnesota</institution><addr-line><named-content content-type="city">Minneapolis</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Thomas</surname><given-names>David D</given-names></name><role specific-use="author">Author</role><aff><institution>University of Minnesota</institution><addr-line><named-content content-type="city">Minneapolis</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Pomerantz</surname><given-names>Will</given-names></name><role specific-use="author">Author</role><aff><institution>University of Minnesota</institution><addr-line><named-content content-type="city">Minneapolis</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Freedman</surname><given-names>Tanya S</given-names></name><role specific-use="author">Author</role><aff><institution>University of Minnesota</institution><addr-line><named-content content-type="city">Minneapolis</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Levinson</surname><given-names>Nicholas M</given-names></name><role specific-use="author">Author</role><aff><institution>University of Minnesota</institution><addr-line><named-content content-type="city">Minneapolis</named-content></addr-line><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>We would like to thank the reviewers for their helpful comments. We note that both reviews are strongly supportive with comments including, âa biophysical tour de forceâ (rev #1), âthe study is exemplaryâ (rev #2), and ârepresents a roadmap for future workâ (rev #2). Below we respond to each reviewer comment.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1</bold></p><p>This study provides a detailed and quantitative description of the allosteric mechanisms resulting in the paradoxical activation of BRAF kinase dimers by certain kinase inhibitors. The findings provide a much needed quantiative basis for this phenomenon and may lay the foundation for future drug development efforts aimed at the important cancer target BRAF. The study builds on very evidence obtained by multiple independent biophysical methods.</p><p>Summary:</p><p>The authors quantitatively describe the complex binding equilibria of BRAF and its inhibitors resulting in some cases in the paradoxical activation of BRAF dimer when bound to ATP competitive inhibitors. The authors use a biophysical tour de force involving FRET binding assays, NMR, kinase activity assays and DEER spectroscopy.</p></disp-quote><p>We are gratified by the reviewerâs supportive summary.</p><disp-quote content-type="editor-comment"><p>Strengths:</p><p>The strengths of the study are the beautifully conducted assays that allow for a thorough characterization of the allostery in this complex system. Additionally, the use of F-NMR and DEER spectroscopy provide important insights into the details of the process.The resulting model for binding of inhibitors and dimerization (Fig.4) is very helpful.</p><p>Weaknesses:</p><p>This is a complex system and its communication is inherently challenging. It might be of interest to the broader readership to understand the implications of the model for drug development and therapy.</p></disp-quote><p>We agree with the reviewer that this is a complicated system. With regard to inhibitor development, a key insight is that designing aC-in state inhibitors that avoid paradoxical activation may be non-trivial because these molecules not only induce dimers but also tend to bind the second dimer subunit more weakly than the first, due to allosteric asymmetry and/or inherently different affinities for each RAF isoform. We feel the full implications for future therapeutic development are an extensive topic that is beyond the scope of our work, which is focused on the properties of current inhibitors.</p><disp-quote content-type="editor-comment"><p>Recommendations for the author:</p><p>The experimental work, analysis and resulting model are excellent. I had some difficulty following the complex model in some instances and it may be useful to review the description of the model and see whether it can be made more palatable to the broader readership.I think it would be useful to discuss the model presented in reference 40 (Kholodenko) and to compare it to the presented model here.</p></disp-quote><p>We regret any confusion with regards to the nature of the model. Our analysis was built upon the model developed by Boris Kholodenko as reported in his 2015 Cell Reports paper. This formed the theoretical framework that combined with our experimental data allowed us to parameterize this model to obtain experimental values for the equilibrium constants and allosteric coupling factors.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2</bold></p><p>This manuscript combines elegant biophysical solution measurements to address paradoxical kinase activation by Type II BRAF inhibitors. The novel findings challenge prevailing models, through experiments that are rigorous and carefully controlled. The study is exemplary in the breadth of strategies it uses to address protein kinase dynamics and inhibitor allostery.</p><p>Summary:</p><p>This manuscript uses FRET, 19F-NMR and DEER/EPR solution measurements to examine the allosteric effects of a panel of BRAF inhibitors (BRAFi). These include first-generation aC-out BRAFi, and more recent Type I and Type II aC-in inhibitors. Intermolecular FRET measurements quantify Kd for BRAF dimerization and inhibitor binding to the first and second subunits. Distinct patterns are found between aC-in BRAFi, where Type I BRAFi bind equally well to the first and second subunits within dimeric BRAF. In contrast, Type II BRAFi show stronger affinity for the first subunit and weaker affinity for the second subunit, an effect named &quot;allosteric asymmetry&quot;. Allosteric asymmetry has the potential for Type II inhibitors to promote dimerization while favoring occupancy of only one subunit (BBD form), leading to enrichment of an active dimer.</p><p>Measurements of in vitro BRAF kinase activity correlate amazingly well with the calculated amounts of the half site-inhibited BBD forms with Type II inhibitors. This suggests that the allosteric asymmetry mechanism explains paradoxical activation by this class of inhibitors. DEER/EPR measurements further examine the positioning of helix aC. They show systematic outward movement of aC with Type II inhibitors, relative to the aC-in state with Type I inhibitors, and further show that helix aC adopts multiple states and is therefore dynamic in apo BRAF. This makes a strong case that negative cooperativity between sites in the BRAF dimer can account for paradoxical kinase activation by Type II inhibitors by creating a half site-occupied homodimer, BBD. In contrast, Type I inhibitors and aC-out inhibitors do not fit this model, and are therefore proposed to be explained by previous proposed models involving negative allostery between subunits in BRAF-CRAF heterodimers, RAS priming, and transactivation.</p><p>Strengths:</p><p>This study integrates orthogonal spectroscopic and kinetic strategies to characterize BRAF dynamics and determine how it impacts inhibitor allostery. The unique combination of approaches presented in this study represents a road map for future work in the important area of protein kinase dynamics. The work represents a worthy contribution not only to the field of BRAF regulation but protein kinases in general.</p><p>Weaknesses:</p><p>Some questions remain regarding the proposed model for Type II inhibitors and its comparison to Type I and aC-out inhibitors that would be useful to clarify. Specifically, it would be helpful to address whether the activation of BRAF by Type II inhibitors, while strongly correlated with BBD model predictions in vitro, also depends on CRAF via BRAF-CRAF in cells and therefore overlaps with the mechanisms of paradoxical activation by Type I and aC-out inhibitors.</p></disp-quote><p>We agree with the reviewer that this is a worthy question to be pursued. However, given the substantial experimental effort required for such an endeavor, and the highly supportive nature of the reviewer comments, including that âThis is a strong manuscript that I feel is well above the bar for publicationâ, we believe this effort is more appropriate for a future study.</p><disp-quote content-type="editor-comment"><p>This is a strong manuscript that I feel is well above the bar for publication. Nevertheless, it is recommended that the authors consider addressing the following points in order to support their major conclusions.</p><p>(1) Fig 3D shows similar effects of Type II and Type I inhibitors in the biphasic increase of cellular pMEK/pERK. From this, the authors argue that Type II inhibitors are explained by negative allostery in the BRAF homodimer (based on Fig 2E), while Type I inhibitors are not. But it seems possible that despite the terrific correlation between BBD and BRAF kinase activities measured in vitro, CRAF is still important to explain pathway activation in cells. It also seems conceivable that the calculated %BBD between different Type II inhibitors may not correlate as well with their effects on pathway activation in cells. These possibilities should be addressed.</p></disp-quote><p>We agree with the reviewer that it is likely that CRAF contributes to paradoxical activation by type II inhibitors in cells. It is also likely that other cellular factors such as RAS-priming and membrane recruitment play a role in activation. However, we note that for the type II inhibitors there is good agreement between the biophysical predictions and the concentration regimes in which activation is observed in cells, suggesting that these predictions are capturing a key part of the activation process that occurs in cells.</p><disp-quote content-type="editor-comment"><p>(2) In Fig 2A, is it possible to report the activity of dimeric BRAF-WT in the absence of inhibitor? This would help confirm that the maximal activity measured after titrating inhibitor is indeed consistent with the predicted %BBD population, which would be expected to have half of the specific activity of BB.</p></disp-quote><p>In principle, it is possible to determine the catalytic activity of apo dimers (BB) by combining our model predictions for the concentration of BB dimers and our activity measurements. However, because the activity assays are performed at nanomolar kinase concentrations, whereas the baseline dimerization affinity of BRAF is in the micromolar range, the observed activity of apo BRAF arises from a small subpopulation of dimers (on the order of 4 percent under the conditions of our experiments) and is therefore difficult to define accurately. As a result, we deemed it more suitable to compare our results to published activity measurements derived from 14-3-3-activated dimers which should represent fully dimerized BRAF. This analysis, as reported in Figure 2E, suggests that the BBD activity is approximately half of that of BB.</p><disp-quote content-type="editor-comment"><p>(3) The 19F-NMR experiments make a good case for broadening of the helix aC signal in the BRAF dimer. From this, the study proposes that after inhibitor binds one subunit, the second unoccupied subunit retains dynamics. It would be useful to address this experimentally, if possible. For example, can the 19F-NMR signal be measured in the presence of inhibitor, to support the prediction that the unoccupied subunit is indeed dynamic and samples multiple conformations as in apo BRAF?</p></disp-quote><p>We agree with the reviewer that it would be interesting to determine the dynamic response of BRAF to inhibitor binding. However, this is a challenging undertaking due to the biochemical heterogeneity that occurs at sub saturating inhibitor concentrations. For example, at any given inhibitor concentration, BRAF exists as a mixture of monomers, apo dimers, dimers with one inhibitor molecule, and dimers with two inhibitor molecules bound. This makes it challenging to relate the 19F NMR signal to a single biochemical state. Addressing this would require a substantial experimental effort that we feel is beyond the scope of this study.</p></body></sub-article></article>